CSR Index by Subject
revised January 2001
SUBJECT SOURCE JOURNAL JOURNAL REF. CSR
DATE
Ablation, chemical J of Neurosurgery 1999;90:928-934 Jun 99
" " J Neurosurg 1999;91:294-302 Sep 99
" of subthalamic n. Ann Neur 1999;45:640-651 Jun 99
Acetazolamide (Diamox) Movement Disorders 1993;8:240-241 Nov 95
" for migraine Neurology 1995;45:458-460 Jun 96
Acetylcholine agonist Annals of Neurology 1998;43:311-317 Apr 98
Acetyl-L Carnitine Neur 1996;47:705-711 Oct 96
Activa (Medtronics DBS)Neur 1998;50:ad insert Jun 98
ADHD, and dopamine Lancet 27 Jul 1996:255 Sep 96
Agonists, action Neur 1995;45,S3:S5 May 95
" A-86929 Neur 1997;49:421-426 Oct 97
" N-0923 Mov Disord 1998;13:768-774 Nov 98
" , D1 vs D2 Archives of Neurolo 1997;54(8)Aug Oct 97
" , " Ann Neur 1998;43:202-203 Mar 98
" BAM-1110 Clin Neuropharmacol 1998;21:35-40 Apr 98
" , neuroprotect Ann Neur 1998;44:110-119 Aug 98
" , " Neur 1998;51S2:S10-S12 Sep 98
" , review J Neur N'surg Psych 2000;68:685-690 Jul 00
" , switching Neur 1999;52:1227-1229 Jun 99
" , tolerance of Mov Disord 2000;15:664-668 Oct 00
" and orthost. hyp. Arch Neur 2000;57:1461-63 Nov 00
" " " " Lancet 21 Oct 2000:1498 Dec 00
" , why effect lost Mov Disord 2000;15:804-812 Dec 00
Akineton (biperiden) Mov Disord 1999;14:252-255 May 99
Albuterol helps PD Neur 1994;8:1511-1513 Dec 94
Alpha-synuclein Science News 18 Oct 1997;255 Nov 97
" in Lewy bodies Arch Neur 1998;55:1555ff Mar 98
" no mutant found Ann Neur 1998;43:394-397 Apr 98
" " " " Ann Neur 1998;44:270-273 Sep 98
" " " " J Neur N'surg Psych 1998;64:378-379 Oct 98
" mutations clump Lancet 7 Nov 98;1529 Dec 98
" " " Lancet 24 Oct 98;1328-29 Dec 98
" " " Nat Med 1998;4:1318-1320 Dec 98
" , gene for Ann Neur 1999;46:374-381 Oct 99
" , " Neur 2000;53:2097-2102 Feb 00
Alternative medicine British Medical J 17 Aug 1996 Oct 96
" " BMJ 21 Nov 98:1408 Jan 99
Alzheimer's and PD Ann Neur 1995;37:300-312 Apr 95
" " " J Neur N'surg Psych 1996;61:391-387 Nov 96
" " " Neur 1999;52:719-724 Apr 99
" " " Neur 2000;54:1208 May 00
Amantadine (Symmetrel) Neur 1996;46:1551-1556 Jul 96
" for stroke Lancet 3 April 1999:1157 May 99
" inhibits NMDA Neur 1998;50:1323-1326 Jul 98
" summary Neur 1998;50:1211-1212 Jul 98
" withdrawal Neur 1998;50:1456-1458 Jul 98
" for LID Lancet 14 Aug 99:566-567 Sep 99
" ,skin ulcers from Neur 1999;53:1862-65 Jan 00
" , " " " Neur 2000;55:456-457 Sep 00
" for dyskinesia J Neur N'surg Psych 2000;68:267 Mar 00
" " " Clin Neuropharm 2000;23:82-85 Jun 00
" " " Mov Disord 2000;15:873-878 Dec 00
Aminophylline Br J Clin Pharmacol 1997;43:119-121 Sep 97
ANA vs AAN; annual mtg Ann Neur 2000;48:407ff Dec 00
Annexin V in CSF Mov Disord 1999;14:1008-16 Jan 00
Anorectal function Mov Disord 2000;15:71-76 Feb 00
Anosmia Arch Neur 1998;55:84-90 Feb 98
Anticipation (onset) Neur 1996;47:1512-1517 Feb 97
Antioxidants, dietary Mov Disord 1997;12:190-195 May 97
Anxiety precedes motor Mov Disord 2000;15:669-677 Oct 00
Apolipoprotein E J Neur N'surg Psych 1996;61:347-351 Nov 96
" not PD marker J Neur N'surg Psych 1997;63:394-395 Nov 97
" marks AD and PD Ann Neur 1997;42:655-658 Nov 97
" not PD marker Ann Neur 1998;44:294 Sep 98
" , hallucinations Clin Neuropharm 1999;22:226-230 Sep 99
APOMORPHINE, PD effcts J Neur N'surg Psych 1994;8:998-1001 Dec 94
" vs levodopa J Neur N'surg Psych 1996;61:634-637 Aug 96
" vs Madopar Clin Neuropharm 1997;20:165-167 May 97
" nasal spray Clin Neuropharm 1997;20:245-252 Sep 97
" fast-acting BMJ 28 Feb 98;641 Mar 98
" nasal spray Mov Disord 1998;13:782-787 Nov 98
" injected J Neur N'surg Psych 1998;65:709-716 Dec 98
" to test LID Neur 1997;48:369-372 Mar 97
" pallidotomy test Mov Disord 1998;13:533-535 Jul 98
" quiets GPi Mov Disord 1999;14:45-49 Mar 99
" vs biperiden Mov Disord 1999;14:252-255 May 99
" availability Lancet 1995;345:517-518 Apr 95
" dosage determ Clin Neuropharm 1998;21:152-158 Jul 98
" and erection Mov Disord 1998;13:536-539 Jul 98
" and levodopa Clin Neuropharm 1998;21:86-92 Jun 98
" " " Clin Neuropharm 1999;22:1-4 Mar 99
" and libido Clin Neuropharm 1997;20:140-147 May 97
" formulation Mov Disord 1998;13:52-55 Mar 98
" pharmacology Clin Neuropharm 1998;21:159-168 Aug 98
" " Mov Disord 1999;14:612-618 Oct 99
", self-injection J Neur N'surg Psych 1995;58:681-687 Jul 95
", sublingual Mov Disord 1999;14:664-668 Sep 99
" caused nodules J Neur N'surg Psych 2000;68:260 Mar 00
" by inj. vs ldopa Mov Disord 2000;15:789-794 Dec 00
APOPTOSIS Ann Neur 1995;38:839-851 Feb 96
" suspected Science News 16 Nov 96:316 Dec 96
" tutorial Science 21 Feb 97;1081-82 Mar 97
" natural in rats J Neurosci 1997;17:1075-1085 Apr 97
" from gene p53 J Neurosci 1997;17:1397-1405 Apr 97
" not found postmortMov Disord 1998;13:221-227 May 98
" , caspase Nature Med 1997;3:954-955 Oct 97
" , " Nat Med 1999;5:97-100 Feb 99
" ,L-dopa induced Mov Disord 1997;12:17-23 Feb 97
" , review JAMA 28 Jan 98;300-307 Mar 98
" , " Clin Neuropharm 1999;22:137-150 Sep 99
" , protection from Ann Neur 1999;46:587-597 Nov 99
Appetite increase Neur 1997;49:310-311 Aug 97
Aptiganel Clin Neuropharm 1997;20:311-321 Sep 97
Artane, withdrawal Ann Neur 1997;41:133 Mar 97
Aspiration risk Brain 2000;123:1863-73 Oct 00
Assisted suicide Neur 1998;50:596-598 Apr 98
" " Lancet 6 Mar 1999:821 Apr 99
" " Lancet 6 Nov 1999;1623 Jan 00
Attention deficit Clin Neuropharm 1998;21:108-117 Jun 98
Autonomic deficit Neur 1997;48:662-667 Apr 97
" sorts PD from MSA Neur 1999;53:1020-25: Nov 99
" " " " " Neur 2000;54:963-968 Apr 00
Autopsy, data source Neur 1999;53:1342-1344 Dec 99
Autosomal-d, dementia Ann Neur 1998;43:768-781 Jul 98
Axial motor control J Neur N'surg Psych 1996;61:645-648 Feb 97
BAM-1110 Clin Neuropharm 1998;21:35-40 Apr 98
Behavioral treatment Mov Disord 1997;12:306-314 Aug 97
Biochemical aspects Neur 1998;51S2:S2-S9 Sep 98
Biperiden (Akineton) Mov Disord 1999;14:252-255 May 99
Blink reflex, and PD J Neurosci 1996;16:7308-7330 Dec 96
" rate J Neur N'surg Psych 1998;64:320-324: May 98
" " and levodopa Mov Disord 2000;15:982-985 Dec 00
Botulinum toxin Neur 1995;45:822-824 Jun 96
" for dystonia Archives of Neur 1996;53:617-624 Aug 96
" for blepharospasm J Neur N'surg Psych 1996;61:693 Aug 96
" for constipation Mov Disord 19997;12:764-766 Nov 97
Boxers, parkinsonism J Neur N'surg Psych 1995;58:688-691 Jul 95
Brain injury Neur 1996;47:1358-1359 Jan 97
Bradykinesia Brain 1996;119:801-813 Sep 96
" apomorphine test Clin Neuropharm 1997;20:402-408 Dec 97
" training helps Brain 1998;121:505-514 Apr 98
" not visual-control Brain 1998;121:755-766 Jun 98
" and pallidotomy Neur 1998:51:796-803 Oct 98
" non-PD factors Mov Disord 2000;15:843-849 Dec 00
Breast milk Neur 1998;50:1920-1921 Aug 98
Bromocriptine J Neur N'surg Psych 1994;8:903-910 Dec 94
" neuroprotective? Lancet 20 Jan 1996:196 Mar 96
" with levodopa Clin Neuropharm 1997;20;67-76 May 97
" trials survey Mov Disord 2000;15:55-64 Apr 00
Bruxism Mov Disord 1997;12:73-78 Feb 97
Budipine, for tremor Clin Neuropharm 1999;22:115-119 May 99
Cabergoline Arch Neur 1994;51:1236-1241 Jan 95
" long-lasting Lancet 11 Nov 1995:1290 Dec 95
" " " J Neur N'surg Psych 2000;68:ad Feb 00
" superior agonist Neur 1996;46:1062-1065 Jun 96
" good for early PD Neur 1997;48:363-368 Mar 97
" also for advanced Clin Neuropharm 1997;20:455-465 Dec 97
Calcium deficiency Mov Disord 1997;12:612-613 Sep 97
Cancer mortality in PD Neur 1999;52:395-398 Mar 99
" " debate Neur 1999;53:1158-59 Nov 99
CAPSIT-PD program Mov Disord 1999;14:572-584 Sep 99
Carbidopa, stability Mov Disord 1997;12:608-610 Sep 97
Carbon monoxide Arch Neur 2000;57:1214-18 Sep 00
Cardiac sympathetic n J Neur N'surg Psych 1999;67:189-194 Sep 99
Caregivers, effect on Mov Disord 1998;13:20-28 Mar 98
Carnitine, Acetyl-L Neur 1996:47:705-711 Oct 96
Carotid body, graft Science News 24 April 1999:260 May 99
Cerebellum, in ET Neur 1996;46:1200-1205 Jun 96
" ethanol effect on Ann Neur 1996;39:650-658 Jun 96
" cognitive function Science 28 Mar 97:1940-43 May 97
Cerebrospinal fluid J Neur N'surg Psych 1997;63:754-758 Feb 98
" as diagnostic aid Mov Disord 1998;13:70-77 May 98
" neurotoxic in PD? Arch Neur 1999;56:194-200 Mar 99
Chocolate addiction Lancet 19 Dec 98:1992 Feb 99
" and red wine Lancet 21 Sep 96:834 Oct 96
Cinnarizine Mov Disord 1997;12:107-110 Feb 97
" caused parkinsonism Mov Disord 1998;13:453-456 Jul 98
Cisapride Mov Disord 1997;12:423-425 Aug 97
Citalopram interaction Clin Neuropharm 1997;20:419-433 May 98
Clonidine useful test Lancet 28 Jun 97:1877-81 Aug 97
" not useful test Lancet 17 Apr 99:1329-30 Jun 99
" " Lancet 24 Jul 99:339-40 Sep 99
CLOZAPINE (Clozaril) Lancet 1995;345:517-518 Apr 95
" for drug-induced d Neur 1995;45:432-434 Apr 95
" for dyskinesia Neur 1997;48:658-662 Apr 97
" for " Neur 1999;52:771-776 Apr 99
" for dystonia Mov Disord 1999;14:652-657 Oct 99
" for schizophrenia BMJ 16 Nov 1996:1262 Jan 97
" for hallucinations J Neur N'surg Psych 1997;63:120 Sep 97
" open trial Clin Neuropharm 1997;20:201-209 Sep 97
" for motor symptoms Mov Disord 1998;13:377-382 Jul 98
" for PD psychosis Lancet 12 Jun 99:2041-42 Jul 99
" " " " Mov Disord 1999;14:128-131 Mar 99
" " " " NEJM 1999;340:801-803 Apr 99
" controlled trial NEJM 1999;340:757-763 Apr 99
" for ET Mov Disord 1999;14:468-472 Jun 99
" relieves "off" Mov Disord 1997;12:159-166 May 97
" for tremor Neur 1997;48:1077-1091 May 97
" " " Neur 1997;49:1587-1590 Feb 98
" lit. review Mov Disord 1997;12:483-496 Sep 97
" cardiac risk Lancet 27 Nov 99;1841-5 Jan 00
" alternative search Neur 2000;55:748-749 Nov 00
Cocaine, effect J Neurosci 1996;16:7670-7677 Jan 97
Coenzyme Q10 Neur 1998;50:793-795 Apr 98
Coffee protective? JAMA 2000;283:2674-79 Jun 00
" " BMJ 3 Jun 00:1492 Jul 00
" " Science News 25 Nov 00:344 Dec 00
Cognitive decline J Neur N'surg Psych 1995;58:51-55 Feb 95
" after thalamotomy J Neur N'surg Psych 1996;60:564-571 Jun 96
" regulatory site of J Neurosci 1996;16:7768-7775 Jan 97
" levodopa role in? Brain 1996;119:2121-32 Mar 97
" early sign in PD? Neur 1997;48:546-547 Mar 97
" " " " " J Neur N'surg Psych 1999;67:323-328 Oct 99
" ages faster in PD Arch Neur 1997;54:296-302 Apr 97
" not from pallidoto Arch Neur 1997;54:947-950 Sep 97
" in PSP,MSA, not PD Arch Neur 1998;55:372-378 Apr 98
" cortical receptors J Neur N'surg Psych 1998;65:155-163 Sep 98
" confirmed in PD Brain 2000;123:340-352 Mar 00
" seen in PET Neur 2000;54:1482-1487 May 00
" not " " " Arch Neur 2000;57:470-475 Jun 00
" due to drug meds Mov Disord 2000;15:613-626 Oct 00
" , perseveration Mov Disord 2000;15:835-842 Dec 00
" as early sign J Neur N'surg Psych 2000;69:838 Jan 01
Color discrimination Neur 1995;45:386-387 Mar 95
" , retinal-cell Brain 1995;118:771-778 Aug 95
Compensatory changes Ann Neur 2000;47:493-503 May 00
Complex I (enzyme) Ann Neur 1996;40:663-671 Nov 96
" in mitochondria Mov Disord 1997;12:3-8 Feb 97
" reduced in PD Mov Disord 1998;13;11-15 Mar 98
COMT, action Neur 1998;50S5:S1-S2 Aug 98
" inhibitors Lancet 25 Apr 98:1221-22 Jun 98
" " prolong "on" Neur 1998;50S5:S3-S14 Aug 98
" " and blood-brain Neur 1998;50S5:S26-S30 Aug 98
" " tolcapone Neur 1998;50S6:S27-S32 Aug 98
" " review Journal of Neur 1998;245-S3 25-34 Jan 99
Constipation Lancet 1995;346:861-864 Nov 95
" cisapride for Mov Disord 1997;12:423-425 Aug 97
" botulinum tox. for Mov Disord 1997;12:764-766 Nov 97
" parameters in PD J Neur N'surg Psych 2000;68:768-770 Jul 00
" psyllium for Mov Disord 1997;12:946-951 Jan 98
Coordination Brain 1998;121:1771-84 Oct 98
" , 2-stimulus J Neur N'surg Psych 1998;65:328-337 Oct 98
" , 2-limb Mov Disord 1997;12:958-968 Jan 98
" , " Brain 1998;121:725-742 Jun 98
" , " Brain 1998;121:743-753 Jun 98
" , " Mov Disord 1998;13:422-427 Sep 98
" , in PD and others Mov Disord 2000;15:627-640 Oct 00
" , BRAIN Test for Mov Disord 2000;15:641-647 Oct 00
Cost of PD care Mov Disord 1998;13:249-254 May 98
Creutzfeldt-Jakob BMJ 7 Nov 98:1290 Dec 98
", mad cow epidemic Lancet 4 Nov 00:1579 Dec 00
DATATOP Arch Neur 1995;52:565-570 Nov 95
" Eldepryl transient Ann Neur 1996;39:29-36 Mar 96
" criticism, reply Ann Neur 1996;40:946-949 Mar 97
" , end point in Mov Disord 1997;12:183-189 May 97
" , mortality Ann Neur 1998;43:318-325 Apr 98
Degeneration, pattern Brain 1997;120:2197-2206Feb 98
DEEP-BRAIN STIMULATION Arch Neur 1996;53:898-903 Oct 96
DBS and cognition Ann Neur 1999;46:217-223 Sep 99
" " " Mov Disord 2000;15:136-139 Feb 00
" " " Brain 2000;123:1142-54 Jul 00
" " " Neur 2000;55:411-418 Sep 00
" no adjacent damage Ann Neur 2000;48:372-376 Oct 00
" GP for dyskinesia Neur 1997;49:259-253 Aug 97
" GPi for many sympt J Neurosurg 1997;87:491-498 Nov 97
" several test sites Mov Disord 1997;12:727-737 Nov 97
" four GP sites Neur 1997;49:1564-1569 Feb 98
" GPi J Neurosurg 1998;89:713-718 Dec 98
" " Ann Neur 1998;44:953-961 Jan 99
" " J Neur N'surg Psych 1999;66:297-304 Apr 99
" " site-sensitive J Neur N'surg Psych 1999;67:315-321 Oct 99
" " for dystonia Neur 1999;53:871-874 Oct 99
" " failures Neur 2000;55:728-730 Nov 00
" PET: GPi vs STN Ann Neur 1997;42:283-291 Oct 97
" vent GP vs dorsal Ann Neur 1998;43:180-192 Mar 98
" GPi vs STN Brain 1998;121:451-457 Apr 98
" GP, STN, akinesia Ann Neur 1999;45:473-488 May 99
" STN for dyskinesia Neur 1998;51:850-855 Oct 98
" " " " J Neur N'surg Psych 2000;68:122-123 Feb 00
" " , motor cortex Arch Neur 1999;56:997-1003 Sep 99
" " , 1-yr followup NEJM 1998;16:1105-1111 Nov 98
" " , 6-mo " J Neurosurg 2000;92:615-625 May 00
" " , for tremor Mov Disord 1998;13:907-914 Dec 98
" " , " " Brain 1999;122:1919-31 Nov 99
" " , for ET Neur 1999;53:1447-1450 Dec 99
" " , " " Neur 2000;54:2342-2344 Aug 00
" " , varying power Brain 1999;122:1133-46 Jul 99
" " general benefit Neur 1999;53:85-90 Aug 99
" " " " Arch Neur 2000;57:983-988 Sep 00
" " bilat vs unil Neur 1999;53:561-566 Sep 99
" ", handwriting Mov Disord 1999;14:964-971 Jan 00
" " speech control J Neur N'surg Psych 1999;67:329-333 Oct 99
" ", saccades J Neur N'surg Psych 2000;68:382-384 Apr 00
" ", 6mo followup Arch Neur 2000;57:461-465 Jun 00
" " enhances l-dopa J Neur N'surg Psych 2000;68:595-600 Jun 00
" " impairs cognit. Brain 2000;123:2091-2108Nov 00
" THALAMUS, for ET Mov Disord 1998;13:690-692 Sep 98
" " improves ADL Mov Disord 1998;13:78-83 Mar 98
" " " " Neur 1999;53:1774-80 Jan 00
" " Vim for ET, PD Ann Neur 1997;42:292-299 Oct 97
" " " dyskinesia J Neur N'surg Psych 1999;67:308-314 Oct 99
" " " for tremor Neur 1996;46:1150-1153 Jun 96
" " " " J Neurosurg 1999;91:68-72 Aug 99
" " " " Mov Disord 1999;14:964-971 Jan 00
" " " head tremor Mov Disord 1999;14:847-850 Oct 99
" " safe, effective Neur 1998;51:1063-1069 Nov 98
" " " " J Neur N'surg Psych 1999;66:289-296 Apr 99
" effect on CSF Clin Neuropharm 1999;22:231-238 Sep 99
" units defective BMJ 12 Dec 98:1658-59 Feb 99
" for ET Mov Disord 1997;12:337-341 Aug 97
" for LID J Neur N'surg Psych 1999;66:549-550 May 99
" , Medtronics Neur 1998;50:ad Jun 98
" , and MRI J Neurosurg 1999;90:585-590 Apr 99
" , parameters Mov Disord 1998;13:648-652 Sep 98
" , 8-yr review Mov Disord 1998;13S3:119-125 Feb 99
" , technique Ann Neur 1998;44:622-628 Nov 98
" , voice tremor Neur 1998;50:796-789 Apr 98
" vs pallidotomy Nat Med 1997;3:671-674 Jul 97
" " Nat Med 1997;3:602-603 Jul 97
" " J Neurosurg 1997;87:700-705 Dec 97
" " Lancet 25 Oct 1997:1224 Dec 97
" " Mov Disord 1999;14:50-56 Mar 99
" , value for PD Neur 2000;55:184 Aug 00
Dementia and APOE-(2 Neur 2000;54:1272-76 May 00
Dementia, Downs and J Neur N'surg Psych 1997;62:289 Apr 97
" , estrogen and Neur 1998;50:1141-1143 Jun 98
" ,frontotemporal Ann Neur 1997;41:706-715 Jul 97
" , " Ann Neur 1998;42:794-798 Mar 98
" , incidence in PD Neur 1995;45:705-708 Jun 96
" , " Arch Neur 1996;53:538-542 Jul 96
" , " Neur 1997;49:1570-1576 Feb 98
" , " Neur 1998;50S6:S33-S38 Aug 98
" , " Neur 2000;54:1596-1603 May 00
" , and Lewy bodies Neur 2000;54:1916-1921 Jul 00
" , PD vs AD Neur 1995;45:1025 Jul 95
" , preclinical Neur 1995;45:1691-1696 Jan 96
" , " J Neur N'surg Psych 1998;64:178-183 Apr 98
" , " Arch Neur 1998;55:674-680 Jun 98
" , " , MRI J Neur N'surg Psych 1999;67:20-26 Aug 99
" , tacrine for J Neur N'surg Psych 1996;61:324-325 Oct 96
" , wine prevents BMJ 5 Apr 97:997 May 97
Dependency Mov Disord 1997;12:910-915 Jan 98
Depression Arch Neur 1996;53:175-179 Mar 96
" Neur 1996;47:1148-1152 Jan 97
" Arch Neur 1997;54:625-630 Jun 97
" J Neur N'surg Psych 1997;63:590-596 Jan 98
" from SN DBS Science News 28 Nov 98:344 Dec 98
" , incidence Mov Disord 1998;13:29-33 Mar 98
" " J Neur N'surg Psych 1999;65:492-496 Nov 99
" in DLBD Neur 1998;50:573 Mar 98
" symposium 1997 Neur 1999;52S3:S1-S29: Jun 99
" , tutorial BMJ 13 May 00:1287-8 Jul 00
" , drugs for in PD Int J Ger Psych 1999;14:711-718 Oct 99
" and sex life in PD J Neur N'surg Psych 2000;69:550-552 Nov 00
Desynchronization Mov Disord 1998;13:653-660 Sep 98
" , PD vs PSP Mov Disord 1999;14:634-641 Sep 99
Dextromethorphan Neur 1998;51:203-206 Aug 98
DHEA Lancet 18 Jul 1998:208 Sep 98
Diagnosis, clinical Brain 1997;120:75-90 Apr 97
", " J Neur N'surg Psych 1997;62:245-252 Apr 97
", " Clin Neuropharm 1997;20:239-244 Sep 97
", " Brain 1997;120:1877-83 Dec 97
", " Arch Neur 1998;55:372-378 Apr 98
", " Arch Neur 1999;56:33-39 Mar 99
", " J Neur N'surg Psych 2000;69:434-440 May 00
", MRI Brain 1997;120:1541-52 Nov 97
", " Neur 2000;54:697-202 Mar 00
" in DATATOP Arch Neur 2000;57:369-372 Apr 00
" test battery Mov Disord 2000;15:467-478 Jul 00
" by acute challenge J Neur N'surg Psych 2000;69:590-594 Dec 00
" by balance test Mov Disord 2000;15:850-861 Dec 00
Dihydrexidine Clin Neuropharm 1998;21:339-343 Feb 99
Dimethyl Selegiline J Neurochem 1997;68:434-436 Aug 97
DLBD J Neur N'surg Psych 1996;60:531-538 Jun 96
" ,FD-PET diagnosis Neur 1996;47:462-466 Sep 96
Domperidone Mov Disord 1997;12:952-957 Jan 98
DOPAMINE addiction J Neur N'surg Psych 2000;68:423-428 May 00
" " J Neur N'surg Psych 2000;68:404 May 00
" agonists Neur 1998:50S6:S23-S26 Aug 98
" as diuretic Lancet 29 Dec 00:3139-43 Jan 01
" , distribution Neur 1999;53:1212-1218 Dec 99
" , exogenous Neur 1998;50S5:S17-S25 Aug 98
" neurons Mov Disord 1997;12:885-897 Jan 98
" " not exclusive Lancet 9 Sep 2000;917 Oct 00
" " in striatum Lancet 1 Jul 2000;44-45 Aug 00
" , non-PD use BMJ 8 Mar 97:689-690 Apr 97
" receptor location J Neurosci 1996;16:6579-6591 Nov 96
" " changes Mov Disord 1997;12:33-38 Feb 97
" " " Mov Disord 1998;13:788-797 Nov 98
" pathway gene mutan Neur 1997;48:1589-1593 Jul 97
" regulation Ann Neur s999;46:359-365 Oct 99
" storage sites J Neurosci 1996;16:4135-4145 Nov 96
" regional function Brain 1999;122:1637-50 Oct 99
" transporter functi Science 16 Feb 1996:909 Mar 96
" " function J Neurosci 1997;17:960-974 Apr 97
" " " Mov Disord 1997;12:629-633 Nov 97
" " PET study Neur 1997;48:1578-1583 Jul 97
" " SPECT " Arch Neur 2000;57:205-208 Mar 00
" " gene anomaly Mov Disord 1997;12;760-763 Nov 97
" " " " Neur 1997;49:1577-1579 Feb 98
" " suspect in PD Ann Neur 1998;43:555-560 Jun 98
" " " " " J Neur N'surg Psych 1998;65:164-169 Sep 98
DOPASCAN, SPECT marker Neur 2000;55:1540-1547 Jan 01
Down's syndrome Neur 1994;44:2419 Feb 95
Driving ability JAMA 17 Jan 1996:182 Feb 96
" J Neur N'surg Psych 1996;61:621-627 Aug 96
" J Neur N'surg Psych 1998;64:325-330 May 98
Drooling Neur 2000;54:244-247 Feb 00
Drug industry hype Time 21 Oct 1996:92 Nov 96
" Ann Neur 1997;42:Aug Sep 97
" Arch Neur 1997;54:1508-1509 Jan 98
Drug strategy Neur 1997;49S1:S2-S62 Aug 97
" " Clin Neuropharm 1998;17S2:14-18 May 98
" " Neur 1998;50S6:S18-S22 Aug 98
" therapy, general Neur 1998;50S6:S1-S48 Aug 98
" " , " Neur 1998;50S6:S11-S14 Aug 98
" " , history Neur 1998;50S6:S2-S10 Aug 98
DYSKINESIA Neur 1997;48:369-372 Mar 97
" , amantadine for Neur 1998;50:1323-1326 Jul 98
" , " " Mov Disord 1998;13:798-802 Nov 98
" , apomorphine for BMJ 18 Feb 98;641 Mar 98
" , from apomorphine Clin Neuropharm 1999;22:216-219 Sep 99
" , clozapine for Neur 1997;48:658-682 Apr 97
" , L-dopa-induced Mov Disord 1997;12:148-158 May 97
" , " (LID) Neur 1997;49:717-723 Oct 97
" , PET study Ann Neur 1998;42:720-726 Mar 98
" , pallidotomy for Brain 1998;121:50-75 Mar 98
" , postsynaptic Neur 1998;50:573 Mar 98
" , quantified Mov Disord 1999;14:754-763 Oct 99
" , SPECT study Brain 1998;121:527-533 Apr 98
" , eye movements Mov Disord 1998;13:731-734 Sep 98
" , various drugs forMov Disord 1998;13:871-876 Dec 98
" , tasks worsen Mov Disord 1999;14:242-245 May 99
" , progression Mov Disord 1999;14:605-611 Sep 99
" , rating scale Mov Disord 1999;14:448-455 Jun 99
" , firing rate Ann Neur 1999;46:732-738 Jan 00
" , assessment J Neur N'surg Psych 2000;68:196-201 Mar 00
" , Bermuda conferen Ann Neur 2000;47S1:1-203 May 00
Dyspnoea, lost sense ofLancet 26 Aug 00:739-740 Oct 00
Dystonia and pallidot- J Neur N'surg Psych 1998;65:604-605 Nov 98
" " " J Neurosurg 1999;90:974-976 Jun 99
" , dopa-responsive Ann Neur 1998;44:758-762 Dec 98
" , early-morning Neur 1998;51:283-285 Sep 98
" etiology J Neur N'surg Psych 1998;65:436-445 Nov 98
" , hereditary Neur 1998;50:517-519 Mar 98
" , post-stroke Arch Neur 1999;56:982-989 Sep 99
" , rapid-onset Ann Neur 1998;43:521-526 Jun 98
" , " Mov Disord 1999;14:132-137 Mar 99
" , " and 19q13 Ann Neur 1999;46:176-182 Sep 99
Eldepryl (selegiline) Ann Neur 1994;36;759-764 Dec 94
Electroconvulsive (PSP)Neur 1996;46:1284-1286 Jun 96
" (PD) J Neur N'surg Psych 1996;61:693-694 Aug 96
Encephalitis, childhoodJ Neur N'surg Psych 1996;60:589 Jun 96
" " J Neur N'surg Psych 1998;64:5 Feb 98
Entacapone (Comtan) J Neur N'surg Psych 1996;60:36-40 Feb 96
" Mov Disord 1997;12:497-505 Sep 97
" Ann Neur 1997;42:747-755 Dec 97
" Mov Disord 1997;12:935-945 Jan 98
" Lancet 25 Apr 98:1221-22 Jun 98
" Neur 1998;51:1309-1314 Dec 98
" Neur 1998;51:1309-1314 Jan 99
" J Neur N'surg Psych 1999;67:(advt) Jul 99
" J Neur N'surg Psych 2000;68:589-596 Jun 00
Enteric nervous system New England J Med 25 Apr 96:1106-15 Jun 96
Enriched environment Nat Med 1999;5:448-453 May 99
ESSENTIAL TREMOR, VIM Neur 1996;46:1150-1153 Jun 96
ET , aminophylline Br J Clin Pharmacol 1997;43:119-121 Sep 97
" and PD families Neur 1995;45:645-648 Jun 96
" , botulinum for Neur 1995;45:822-824 Jun 96
" , kinetic v postur Mov Disord 1998;13:803-808 Nov 98
" , DBS for Mov Disord 1997;12:337-341 Aug 97
" , " " Neur 2000;54:2342-2344 Aug 00
" , diagnosis Mov Disord 1997;12:973-976 Jan 98
" , " Mov Disord 1998;13:287-293 May 98
" , " Lancet 1 May 99:1498-99 Jun 99
" , " Mov Disord 1999;14:462-467 Jun 99
" , " Arch Neur 1999;56:841-846 Aug 99
" questionnaire Mov Disord 2000;15:516-523 Jul 00
" , v gender and age Mov Disord 1997;12:969-972 Jan 98
" , asymmetry featureArch Neur 1998;55:1553-59 Feb 99
" , etiology Neur 1996;46:1200-1205 Jun 96
" , " needs study Neuroepidemiology 1997;16:124-133 Sep 97
" , " " " Arch Neur 1997;54:289-294 Sep 97
" , " " " Arch Neur 1997;54:197-200 Sep 97
" , " " " Neur 1998;50:1351-1357 Jul 98
" , " " " Mov Disord 1999;14:456-461 Jun 99
" features like PD Mov Disord 2000;15:511-515 Jul 00
" is hereditary Neur 1996;47:264-265 Sep 96
" and cerebellum Ann Neur 1997;41:32-40 Mar 97
" after pons stroke J Neurol Sci 1997;149:195-196 Aug 97
" and thalamus J Neur N'surg Psych 1998;64:273-276 Apr 98
" , gene for Mov Disord 1997;12:859-864 Jan 98
" , incidence Mov Disord 1998;13:5-10 Mar 98
" , " Arch Neur 1998;55:823-828 Aug 98
" measurement Mov Disord 1999;14:288-294 May 99
" and migraine Neur 1996;46:458-460 Jun 96
" and ethanol Ann Neur 1996;39:650-658 Jun 96
" and methazolamide Neur 1996;47:1331-1332 Jan 97
" , tutorial summary The Neurologist 1997;3:305-321 Nov 97
" , " " Neur 2000;54S4:S1-S46 Jul 00
" may precede PD Neur 1999;52:1422-1426 Jun 99
" distinct subtypes Arch Neur 2000;57:1194-98 Sep 00
" frequency, aging Neur 2000;55:1547-1551 Jan 01
Estradiol, no effect Clin Neuropharm 1999;22:93-97 May 99
Estrogen benefits PD Neur 1999;52:1417-1421 Jun 99
" " " Neur 2000:54:2292-2298 Aug 00
" , effects of Clin Neuropharm 1999;22:318-326 Feb 00
" loss effects Lancet 9 Dec 00:1993 Jan 01
Ethanol and ET Ann Neur 1996;39:650-658 Jun 96
" Ann Neur 1996;40:950 Mar 97
ETIOLOGY of PD (Asians)Neur 1996;46:1044-1050 Jun 96
",legumes, vitamin E Neur 1996;46:1270-1274 Jun 96
",pesticides, smoking Neur 1996;46:1275-1284 Jun 96
",compehensive review J Neur N'surg Psych 1996;61:4-16 Aug 96
",futile search Arch Neur 1996;53:721 Sep 96
",food/drink habits Neur 1996;47:636-643 Oct 96
",nutrients Neur 1996;47:644-650 Oct 96
",motor vs. memory Arch Neur 1997;54:145-150 Mar 97
",pallidum activity Ann Neur 1997;42:767-775 Dec 97
",smoking, age Neur 1997;49:1267-1272 Jan 98
",farm, well, ethnic Neur 1998;50:279-281 Mar 98
",MPTP endog. analog Lancet 21 Mar 98:850-851 Apr 98
",farming, pesticide Neur 1998;50:1346-1350 Jul 98
",rural, well, genes Lancet 19 Dec 98:1986-87 Feb 99
",males, rural Neur 1999;52:302-308 Mar 99
",detection, familial Neur 1999;52:757-762 Apr 99
",autoimmune Arch Neur 1998;55:1075-1080 Oct 98
",breakthrough Lancet 21 Oct 98:1344-46 Dec 98
", " " Lancet 21 Oct 98:1328-29 Dec 98
",pesticide Neur 1999;52:1467-1471 Jun 99
",smoking, farming Mov Disord 1999;14:928-939 Jan 00
",jet fuel BMJ 2 Aug 97:275 Sep 97
",hydrocarb. solvents Neur 2000;55:667-673 Nov 00
Event-related potentialMov Disord 1998;13:262-267 May 98
Evoked response " J Neur N'surg Psych 1999;65:497-503 Nov 99
Executive control Brain 1998;121:815-842 Jun 98
Exercise, effect of J Neur N'surg Psych 1998;65:531-546 Nov 98
" and ldopa dosage Mov Disord 2000;15:862-868 Dec 00
Expression Neur 1995;45:1696-1702 Jan 96
Eye movement Neur 1994;44:2285 Jan 95
Falling, onset in PD Mov Disord 1999;14:947-950 Jan 00
" risk in elderly Ann Neur 2000;48:268 Sep 00
" , stability test Mov Disord 2000;15:255-268 May 00
Fatigue, chronic JAMA 8 Oct 97;1179-85 Nov 97
" " JAMA 1998;280:1061-66 Oct 98
" " JAMA 1998;280:1084 Oct 98
" , PD symptom Neur 1998;51:1583-1586 Jan 99
" , " Mov Disord 1999;14:237-241 May 99
" , " J Neur N'surg Psych 2000;69:289 Oct 00
FETAL TRANSPLANT Ann Neur 1995;38:379-388 Oct 95
" , partial success Brain 1996;119:41-50 Apr 96
" , news review Lancet 26 Oct 1996;1159 Dec 96
" , animal Nature Med 1997;3:964-969 Oct 97
" , bovine BMJ 9 May 98:1407 Jun 98
" , " Nat Med 1998;4:569-574 Jun 98
" , cortical function Ann Neur 2000;48:689-695 Dec 00
" , effects J Neurosurg 1997;86:931-942 Jul 97
" , " Mov Disord 1998;13S1:83-87 Jul 98
" , fatal Neur 1997;48:1737-1738 Jul 97
" , " J Neurosurg 1998;89:532-598 Oct 98
" , FDA and Lancet 16 Mar 1997:784 Apr 97
" for Huntington's Exp Neur 1990;149:97-108 May 98
" for stroke victims Science News 21 Oct 2000:269 Nov 00
" , immunosuppression J Neurosurg 1999;91:109-113 Aug 99
" logistics Nat Med 1997;3:1129-1132 Nov 97
" " JAMA 19 Aug 1998:594 Oct 98
" , pig Science News 7 Oct 1995:230 Nov 95
" , " , restrictions Science 24 Jan 1997:473 Mar 97
" , " , USPHS " Lancet 31 Jan 98;343 Mar 98
" , " , virus fears BMJ 1 Mar 1997;625 Apr 97
" , " , " " Lancet 18 Oct 1997:1148 Nov 97
" , " , " " Nature 16 Oct 1997:681-2 Nov 97
" , " , " " Nat Med 1998;4:141-144 Mar 98
" , " , " " Lancet 29 Aug 98:666 Oct 98
" , " , " not foundLancet 1998 Review:26 Feb 99
" , " , " " " Lancet 21 Aug 99:654 Oct 99
" , " , debate about Nat Med 1997;3:474-475 Jul 97
" , " , " " Lancet 20 Sep 1997:868 Nov 97
" , " , " " Lancet 24 Oct 98:1390-91 Dec 98
" , " , " " BMJ 25 Mar 2000;868-9 May 00
" , " , thrived 7 mo Nat Med 1997;3:350-353 Aug 97
" , " Sertoli cells Nat Med 1997;3:1129-1132 Nov 97
" , " , 1st trial Lancet 18 Mar 2000:991 Apr 00
" , " , " Neur 2000;54:1042-1050 Apr 00
" , " , " Science News 25 Mar 2000:197 Apr 00
" , " , production BMJ 25 Mar 2000;825 May 00
" research J Neurosci 1996;16:6966-6974 Dec 96
" " J Neurosci 1996;16:7216-7227 Dec 96
" " Ann Neur 1998;43:387-390 Apr 98
" ", in rats Brain 2000;123:1365-79 Aug 00
" , sequential Brain 1999;122:1121-32 Jul 99
" , controlled trial JAMA 19 May 99:1784 Jun 99
" , substitute cells Science News 22 Aug 98:120-122 Sep 98
" , survival Exp Neur 1997;144:41-46 Aug 97
" , " Ann Neur 1997;42:95-107 Aug 97
" , " Mov Disord 1998;13:383-393 Jul 98
" , " Arch Neur 1999;56:179-187 Mar 99
" , " tirilizad Brain 2000;123:1380-90 Aug 00
" , volume Exp Neur 1997;146:536-545 May 98
" , success in HD Lancet 9 Dec 00:1975-1979Dec 00
Finger control Mov Disord 1998;13:418-421 Sep 98
Fluctuations, motor Mov Disord 1997:12:285-292 Aug 97
" , " Clin Neuropharm 1994;17S2:19-31 May 98
" , " Clin Neuropharm 1994;17S2:7-13 May 98
" , incidence of Mov Disord 2000;15:826-829 Dec 00
" , nonmotor Neur 1996;47:1180-1183 Jan 97
" , plasma Neur 1998;50S6:S15-S17 Aug 98
" , types of Neur 1998;51S2:S25-S29 Sep 98
Flunarizine Movem't Dis 1997;12:107-110 Feb 97
Food And Drug Adm. Nat Med 1997;3:477 Jul 97
Food habits and PD Neur 1996;47:636-643 Oct 96
" Mov Disord 1999;14:21-27 Mar 99
" Mov Disord 1999;14:28-37 Mar 99
Free radicals Science News 18 May 1996:311 Jun 96
Freezing, in non-IPD Mov Disord 1997;12:302-305 Aug 97
Freezing, help for Mov Disord 1997;12:206-215 May 97
" " Mov Disord 1999;14:63-64 Mar 99
" " Mov Disord 2000;15:309-312 May 00
Gabapentin for RLS Clin Neuropharm 1997;20:148-151 May 97
" for ET Mov Disord 1998;13:465-467 Jul 98
" " Arch Neur 1999;56:475-480 Jun 99
" " Arch Neur 1999;56:807-808 Sep 99
" ineffective " Mov Disord 2000;15:678-682 Oct 00
" for PD Mov Disord 1997;12:608 Sep 97
" with propranolol Arch Neur 2000;57:570-571 Jun 00
Gait as assessment Mov Disord 1998;13:900-906 Dec 98
" timing control Mov Disord 1999;14:619-625 Sep 99
" improvement Brain 1996;119:551-558 Jul 96
" " J Neur N'surg Psych 1997;63:556 Nov 97
" " J Neur N'surg Psych 1998;65:580-582 Nov 98
" " Ann Neur 1999;45:329-336 Apr 99
" impairment Brain 1996;119:1705-16 Jan 97
" " Mov Disord 2000;15:830-834 Dec 00
" " Clin Neuropharm 1997;20:183-184 Sep 97
" " Mov Disord 1997;12:682-690 Nov 97
" " Mov Disord 1998;13:255-261 May 98
" parameters Brain 1999;122:1349-55 Sep 99
" brain activity in Brain 1999;122:1271-82 Sep 99
Gambling, pathological Mov Disord 2000;15:869-872 Dec 00
Gamma knife Ann Neur 1996;39:535-538 Jun 96
" J Neurosurg 1998;89:183-193 Sep 98
Ganglioside GM1 Neur 1995;45:1149-1154 Sep 95
" Neur 1998;50:1630-1636 Aug 98
GDNF J Neurosci 1996;16:7206-7215 Dec 96
" J Neurosci 1996;16:8132-8139 Jan 97
" Science 7 Feb 97:838-841 Mar 97
" Ann Neur 1997;42:208-214 Sep 97
" Mov Disord 1998;13S1:49-54 Jul 98
" delivery failure Ann Neur 1999;46:419-424 Oct 99
" by virus vector Lancet 28 Oct 2000:1498 Dec 00
" success in rats J Neurosurg 2000;92:659-670 May 00
Gender differences Clin Neuropharm 1998;21:118-121 Jun 98
GENE CYP2D6, and risk Neur 1996;47:225-230 Sep 96
" " J Neur N'surg Psych 1998;65:781-784 Dec 98
" Mov Disord 1998;13:218-220 May 98
" not a factor Mov Disord 1999;14:230-236 May 99
" " Mov Disord 1999;14:590-595 Sep 99
" , for D4 receptor Mov Disord 1999;14:225-229 May 99
" , " D2 " Mov Disord 2000;15:127-131 Feb 00
" , for MAO-B Mov Disord 1999;14:219-224 May 99
" , mitochondrial Ann Neur 1998;44:873-881 Jan 99
" , mutation Lancet 1995;345:958 Jun 95
" " not found Neur 1995;45:1760-1763 Jan 96
" " " " Clin Neuropharm 1999;22:839-841 Nov 99
" " suspected Science 15 Nov 96;1197-99 Dec 96
" " discounted BMJ 23 Nov 96;1278 Jan 97
" " autosom-domin Ann Neur 1996;40:767-775 Jan 97
" " for PSP Ann Neur 1997;41:277-281 Mar 97
" " not found Ann Neur 1997;41:814 Jul 97
" " alpha-synucleinScience 27 Jun 97:2045 Aug 97
" " not found Arch Neur 2000;57:501-503 Jun 00
" " announced Science News 28 Jun 97:396 Aug 97
" " apolipoprotein Ann Neur 1997;42:655-658 Nov 97
" " susceptibility Lancet 18 Oct 97:1136-9 Nov 97
" " DAT not found Neur 1997;49:1577-1579 Feb 98
" " " found Ann Neur 2000;47:528-531 May 00
" " alpha-k found Ann Neur 1998;43:120-123 Feb 98
" " not sporadic Neur 1998;50:513-514 Mar 98
" " not found J Neur N'surg Psych 1998;64:416 May 98
" " NAT2 found Neur 1998;51:1587-1592 Jan 99
" " " " Mov Disord 2000;15:30-35 Feb 00
" " " suspected Mov Disord 2000;15:714-719 Oct 00
" " not found Neur 1998;51:1757-1759 Jan 99
" " not found J Neur N'surg Psych 1998;65:948-949 Jan 99
" " not found J Neur N'surg Psych 1999;65:518-520 Nov 99
" " juvenile PD Ann Neur 1998;44:835-841 Jan 99
" " not found Arch Neur 1998;55:1521-23 Feb 99
" " not found Neur 1999;52:297-301 Mar 99
" " alpha-syn foundNeur 1999;52:651-654 Mar 99
" " found Ann Neur 1999;45:611-617 Jun 99
" " in sub nigra Mov Disord 1999;14:417-422 Jun 99
" " not found Neur 1999;53:1415-1421 Dec 99
" " not found Neur 1999;53:1570-1572 Dec 99
" " for dyskinesia Neur 1999;53:1425-1430 Dec 99
" " juvenile PD Neur 1999;53:1602-1604 Dec 99
" " ", parkin Ann Neur 2000;48:245-250 Sep 00
" " parkin found Ann Neur 2000;48:65-71 Aug 00
" " found Neur 1999;53:1787-93 Jan 00
" " not found Neur 2000;54:703-709 Mar 00
" " " " Neur 2000;54:1195-1198 May 00
" " ADH4 suspect Mov Disord 2000;15:813-818 Dec 00
GENE TRANSFER THERAPY Science News 29 Jul 1995:73 Aug 95
" , HIV vector Science 12 Apr 1996;263 May 96
" , herpes vector Nat Med 1997;3:357-359 Aug 97
" , " " Brain 1997;120:1245-59 Aug 97
" , " " Mov Disord 2000;15:9-17 Feb 00
" , tutorial review Mov Disord 1998;13S1:59-72 Jul 98
" , " " Arch Neur 1999;56:287-292 May 99
" by mouth Nat Med 1998;4:1131-1135 Nov 98
Ginkgo Biloba extract JAMA 22 Oct 97:1327-32 Nov 97
" Neur 1998;50:1933-1934 Aug 98
" Lancet 4 Jul 1998:36 Aug 98
Glucose tolerance Int J Neur 1994;69:125-130 Jan 96
Glutamate antagonist Ann Neur 1996;39:574-578 Jun 96
" " Ann Neur 1996;39:557-558 Jun 96
" " J Neurosci 1996;16:4231-4239 Nov 96
" " Clin Neuropharm 1997:20:311-321 Sep 97
" " J Neurosci 1996;16:6394-6401 Nov 96
" " Clin Neuropharm 1998;21:28-34 Apr 98
" " Neur 1998;51:203-206 Aug 98
" " Neur 2000;54:1589-1595 May 00
" receptors Neur 1998;51S2:S30-S35 Sep 98
" " Mov Disord 1998;13:798-802 Nov 98
" , toxicity Science 6 Dec 1996:1612 Jan 97
" " J Comp Neur 1998;390:91-101 Apr 98
" and cognition Science News 4 Sep 99:149 Oct 99
Glutamatergic degener- Ann Neur 2000;47:345-352 Apr 00
Glutamic acid RNA Neur 1996;47:219-224 Sep 96
GPe degeneration Mov Disord 1999;14:626-633 Sep 99
Guillain-Barre Ann Neur 1995;38:218-224 Sep 95
Hallucinations Neur 1995;45:659-671 Jun 96
" Arch Neur 1996;53:1265-1268 Jan 97
" J Neur N'surg Psych 1997;63:120 Sep 97
" J Neur N'surg Psych 1997;63:434-440 Nov 97
" Neur 1998;51:811-814 Oct 98
" , incidence Brain 2000;123:733-745 Jun 00
" , auditory J Neur N'surg Psych 1998;64:533-535 Jun 98
" , cause Neur 1998;50:515-517 Mar 98
" , visual Clin Neuropharm 1998;21:289-295 Nov 98
Handwriting J Neur N'surg Psych 1997;63:429-433 Nov 97
Health burdens of PD Mov Disord 1998;13:406-413 Sep 98
" services, use of Mov Disord 1999;14:772-779 Oct 99
Heart affected by PD Neur 1999;52:1269-1271 Jun 99
" " " " Lancet 9 Sep 2000;917 Oct 00
Heriditary, dementia Ann Neur 1998;43:768-781 Jul 98
Heredity Neur 1995;45:502-506 Apr 95
" Ann Neur 1995;38:373-378 Oct 95
" Science News 6 Jan 96:4 Feb 96
" Neur 1996;46:1275-1284 Jun 96
" Neur 1996;47:155-160 Sep 96
" Neur 1996;47:160-166 Sep 96
" Ann Neur 1997;41:265-268 Mar 97
" Ann Neur 1997;41:222-229 Mar 97
" Ann Neur 1997;42:638-643 Nov 97
" Lancet 18 Oct 97:1136-39 Nov 97
" Neur 1999;52:1876-1882 Jul 99
" BMJ 19 Jun 99:1641-42 Aug 99
" Neur 2000;54:504-507 Mar 00
" recessive v dominantJ Neur N'surg Psych 2000;69:107-109 Aug 00
" twin study JAMA 21 JN 1999:341-46 Feb 99
" " " Ann Neur 1999;45:577-582 Jun 99
" " " Neur 1999;53:566-572 Sep 99
" " " Neur 2000;54:1721-1722 Jun 00
" " " Ann Neur 2000;47:682 Jun 00
" Tunisian Neur 2000;1603-1609 May 00
Histaminergic neurons Neur 1996;46:1693-1696 Jul 96
Hitler's PD observed Mov Disord 1997;12:239-240 May 97
HIV patients with PD Mov Disord 1998;13:684-689 Sep 98
Hoehn-Yahr article Neur 1998;50:318ff Mar 98
Homocysteine, levodopa Lancet 10 Jul 99:126 Aug 99
" , and gene mutant Neur 2000;55:437-440 Sep 00
Huntington's Lancet 16 Jan 99:240-241 Feb 99
" and PD J Neur N'surg Psych 1998;65:577-579 Nov 98
" mistaken for PD J Neur N'surg Psych 2000;68:238-241 Mar 00
Hydrocarbon, caused by Ann Neur 1996;40:922-925 Mar 97
Hypophonia Neur 1998;51:1592-1598 Jan 99
Hypotension after meal Mov Disord 1997;12:877-884 Jan 98
Hypothalamus, impaired Neur 1997;49:610-613 Oct 97
Hypoxia response lost Lancet 26 Aug 00:739-740 Oct 00
" " " Lancet 16 Dec 00:2099 Jan 01
Idazoxan helps L-dopa Mov Disord 1999;14:744-753 Oct 99
Impact and adjustment Mov Disord 2000;15:497-502 Jul 00
Incidence (survey) Neur 1997;48:1277-1281 Jun 97
" " Mov Disord 1998;13:400-405 Aug 98
" " reliability Mov Disord 2000;15:819-825 Dec 00
", Argentina Mov Disord 1997;12:197-205 May 97
", Faroe Isl Neur 1997;49:426-432 Oct 97
", India Ann Neur 1998;43:283-287 Apr 98
", Italy Neur 2000;55:1358-1363 Jan 01
", Olmsted Cty Neur 1999;52:1214-1220 Jun 99
Inderal, for dyskinesiaNeur 1996;46:1548-1551 Jul 96
Infusion pump, enteral Mov Disord 1998;13:336-338 May 98
Iron, possible cause Lancet 8 Jun 1996;1614 Jul 96
" , oxidative stress Mov Disord 1988;13S1:39-45 Jul 98
Iron, elevated Ann Neur 1994;36;876-881 Jan 95
" , " Neur 1995;45:1138-1143 Oct 95
" , " Neur 1997;49:714-717 Oct 97
" , " Neur 1998;50:1138-1140 Jun 98
" , " Mov Disord 1998;13S1:13-16 Jul 98
" , " Brain 1999;122:667-673 Jun 99
" , " with aging Mov Disord 1998;13:281-286 Jun 98
" , MRI scan for Brain 2000;123:2423-31 Jan 01
Jet fuel, hazard of BMJ 2 Aug 97:275 Sep 97
Juvenile PD Neur 1996;47:160-166 Sep 96
" " Neur 1998;51:890-892 Oct 98
" " Mov Disord 1998;13:885-894 Dec 98
" " Ann Neur 1998;44:835-841 Jan 99
" " a distinct type Neur 2000;55:877-879 Nov 00
Kava J Neur N'surg Psych 1995;58:639-640 Jun 95
Keats, John Arch Neur 1994;51:1182-1183 Jan 95
KW-6002 possible help Neur 1999;52:1672-1677 Jun 99
Lamotrigine Neur 1997;48:1282-1286 Jun 97
Latency, autonomic J Neur N'surg Psych 1999;67:620-623 Dec 99
Late treatment of PD J Neur N'surg PSych 1998;65:605-606 Nov 98
Lazabemide Ann Neur 1996;40:99-107 Aug 96
" Clin Neuropharm 1999;22:340-346 Feb 00
Lead-sulfate batteries Neur 1998;50:1885-1886 Aug 98
Learning ability J Neur N'surg Psych 1999;67:27-34 Aug 99
Leksell frame J Neurosurg 1998;88(3) ad Apr 98
" J Neurosurg 1998;88:777-781 Jun 98
Leukemia drugs Ann Neur 1995;37:810-814 Jul 95
LEVODOPA absorption Neur 1996;46:1051-1054 Jun 96
" " Neur 1998;51S2:S36-S40 Sep 98
" , EEG, bradykinesia Mov Disord 1999;14:423-429 Jun 99
" dual-release trial Clin Neuropharm 1997;20:130-139 May 97
" -induced dyskinesia J Neur N'surg Psych 1999;66:549-550 May 99
" LID reversible? Ann Neur 2000;47:655-658 Jun 00
" helps anxiety, mood Neur 1995;45:1757-1760 Jan 96
" , PET study of Neur 1996;46:1430-1436 Jun 96
" vs apomorphine J Neur N'surg Psych 1996;61:634-637 Aug 96
" LONG-TERM EFFECTS Mov Disord 1997;12:103-106 Feb 97
" " on receptors Ann Neur 2000;47:136 Feb 00
" " , PET study of Neur 1999;52:120-125 Feb 99
" " , day's end Clin Neuropharm 2000;23:28-33 Mar 00
" LDR (long duration) Ann Neur 1997;42:245-248 Sep 97
" " shows at 3 weeks Neur 1999;53:557-560 Sep 99
" " and SDR study Ann Neur 1997;42:349-355 Oct 97
" " " " " Clin Neuropharm 1997;20:394-401 Dec 97
" " " " " Ann Neur 1995;38:389-395 Oct 95
" " declines at 1 yr Neur 1999;52:763-767 Apr 99
" " hypothesis Neur 2000;54:247-250 Feb 00
" " dose-dependent Neur 2000;54:1910-1915 Jul 00
" effects loss varies Clin Neuropharm 1997;20:409-418 Dec 97
" complications onset Clin Neuropharm 1997;20:523-530 Feb 98
" " " Clin Neuropharm 1994;17S2:S32-44 May 98
" alters D1 distribut Ann Neur 1999;46:103-111 Aug 99
" , proton MRS study Neur 1997;49:438-444 Oct 97
" ethylester injectab Ann Neur 1996;39:400-404 Apr 96
" for non-PD dystonia Arch Neur 1998;55:1320-1323 Nov 98
" no long-term harm Mov Disord 1999;14:206-218 May 99
" metabolism study Ann Neur 1997;42:300-304 Oct 97
" elevates mood J Neur N'surg Psych 1999;66:541-544: May 99
" for non-PD tremor J Neur N'surg Psych 1999;66:681-684 Jun 99
" overdose effects J Neur N'surg Psych 1999'67:22-24 Aug 99
" half-life declines Neur 1998;51:1076-1089 Nov 98
" sedates at first Clin Neuropharm 1999;22:15-23 Mar 99
" , should use early J Neur N'surg Psych 1995;59:555 Dec 95
" , " " " Neur 1998;51S2:S21-S24 Sep 98
" , " " " Mov Disord 1999;14:716-724 Oct 99
" , avoid in early PD Mov Disord 1999;14:725-730 Oxt 99
" and PD progression Neur 1996;47:Supp 3 Feb 97
" dosage tactics Neur 1997;49:711-713 Oct 97
" not neurotoxic Mov Disord 1997;12:634-638 Nov 97
" " " Lancet 21 Mar 98:851-852 Apr 98
" " " Ann Neur 1998;43:561-575 Jun 98
" " " Neur 1998;50:858-863 Jun 98
" may be toxic Brain Res 1997;777:202-209 Apr 98
" " " " Neur 1998;50S6:S39-S45 Aug 98
" toxicity debated Ann Neur 1998;43:551-554 Jun 98
" no cognitive harm Neur 1998;50:1327-1331 Jul 98
" prolongs survival Lancet 28 May 99:1850-51 Jul 99
" methyl ester Clin Neuropharm 1999;22:281-187 Nov 99
" vs pramiprexole Clin Neuropharm 2000;23:34-54 Mar 00
" " " Lancet 21 Oct 00:1416 Dec 00
" for akathisia Clin Neuropharm 2000;23:59-81 Mar 00
" helps non-PD aged Ann Neur 2000;48:250-253 Sep 00
" long-term effects Brain 2000;123:2297-2305Dec 00
Lewy bodies Arch Neur 1998;55:1555ff Mar 98
" Nat Med 1998;4:1318-1320 Dec 98
Lewy body disease J Neur N'surg Psych 1996;60:531-538 Jun 96
" Neur 1996;47:462-466 Sep 96
" Neur 1997;48:376-380 Mar 97
" Science News 18 Oct 1997:255 Nov 97
" Arch Neur 1998;55:969-978 Sep 98
Lifespan shorter in PD Arch Neur 2000;57:507-512 Jun 00
Liquid Sinemet Neur 1996;47:1493-1495 Feb 97
Liver failure Roche Labs leaflet 1998 (1st version)Jan 99
" " Lancet 28 Feb 98:653 Jan 99
" " Lancet 19 Sep 98:958 Jan 99
" " Lancet 3 Oct 98:1119 Jan 99
" " Lancet 19 Feb 00:591-592 Apr 00
Locus coeruleus Brain 1995;118:131-143 Jun 95
Lymphocyte DA receptor Mov Disord 1999;14:764-771 Oct 99
Machado-Joseph Ann Neur 1995;38:684-687 Nov 95
Macrophage Science News 21 Sep 96:180 Oct 96
Madopar , dispersible Clin Neuropharm 1999;22:356-358 Feb 00
Mag Res Im. diagnosis Neur 2000;55:1239-1240 Dec 00
" Spectroscopy Mov Disord 1998;13:1-2 May 98
" Nat Med 1998;4:1308-1312 Dec 98
" review Arch Neur 1999;56:1446-47 Jan 00
" MSA vs PD Mov Disord 1999;14:423-429 Jun 99
" diagnose PD J Neur N'surg Psych 1999;67:815-818 Jan 00
Magnetic stimulation Brain 1996;119:71-77 May 96
" Brain 1996;119:815-822 Sep 96
" Ann Neur 1996;40:344-355 Oct 96
" Brain 1997;120:1587-1602 Nov 97
" J Neur N'surg Psych 1998;64:33-36 Feb 98
Management of PD Neur 1998;50:Supp3 Apr 98
MAO inhibition, effect J Neurosci 1997;17:2267-2272 May 97
MAO-B Neur 1996;46:1262-1269 Jun 96
" Ann Neur 1996;40:99-107 Aug 96
Mapping basal ganglia Neur 2000;55:377-383 Sep 00
Markers, neurochemical Neur 1996;47:718-726 Oct 96
" " Mov Disord 1997;12:167-174 May 97
" " Ann Neur 1997;41;530-539 May 97
Melatonin BMJ 18 May 96:1242-43 Jun 96
" , antioxidant J Neurosci 1997;17:1683-1690 Apr 97
Memantine NMDA antagon Clin Neuropharm 1999;22:273-276 Nov 99
Memory, Hippocampus Science News 7 Sep 1996:150 Oct 96
Memory and PD Science 6 Sep 96:1263-64 Oct 96
" Science 6 Sep 96:1399-02 Oct 96
" J Neur N'surg Psych 1997;62:410-413 Jun 97
Menstrual effects Neur 1995;45:1028 Jul 95
" Mov Disord 1993;8:240-241 Nov 95
" and hormones Neur 2000;55:1572-1574 Jan 01
Mental/behavioral eff. Ann Neur 1999;45:601-610 Jun 99
" " Mov Disord 2000;15:490-496 Jul 00
Merck Manual (Home Ed) Nat Med 1998;4:242-243 Mar 98
Metaclopramide (Reglan)JAMA 1995;274:1780-82 Jan 96
Metals, exposure to Neur 1997;20:36-41 May 97
Methylsalsolinol Ann Neur 1996;40:119-122 Aug 96
Metronome Lancet 11 May 1996;1337 Jun 96
Micturition Brain 2000;123:781-789 Jun 00
Migraine, DA and Clin Neuropharm 1997;20:36-41 May 97
Mimics of PD Arch Neur 1995;58:294-298 Oct 95
" Brain 1995;118:951-958 Oct 95
" BMJ 16 Mar 1996:724 Apr 96
Mitochondria Science News 5 Aug 1995;84 Sep 95
" Neur 1995;45:2097-2099 Feb 96
" Mov Disord 1997;12:3-16 Feb 97
" Mov Disord 1997;12:639-645 Nov 97
" Ann Neur 1998;44:177-186 Sep 98
" DNA vs nuclear DNA Ann Neur 2000;48:730-736 Dec 00
" " lab studies Ann Neur 2000;48:774-781 Dec 00
" Ann Neur 1998;44:873-881 Jan 99
Moclobemide Clin Neuropharm 1998;21:93-96 Jun 98
" Clin Neuropharm 1998;21:251-254 Sep 98
Mood elevation Neur 1998;50:1890-1892 Aug 98
" swing due to meds J Neur N'surg Psych 2000;69:566-567 Nov 00
Mortality J Neur N'surg Psych 1996;58:293-299 Apr 95
" Arch Neur 1997;54:260-264 Apr 97
" increased in PD J Neur N'surg Psych 1999;67:300-307 Oct 99
" " " J Neur N'surg Psych 2000;68:254-255 Mar 00
Motor cognition Brain 1997;120:1339-53 Oct 97
" Brain 1997;120:1355-75 Oct 97
" cortex stimul Mov Disord 1998;13:84-88 May 98
" " activity Mov Disord 1999;14:790-799 Nov 99
" fluctuations J Neur N'surg Psych 1996;61:634-637 Aug 96
" skill learning Brain 1997;120:1325-37 Oct 97
" neuron degeneratio Mov Disord 2000:15:238-243 May 00
Movement, head and eye Ann Neur 1996;39:749-760 Jul 96
" , coordinated Brain 1997;120:91-102 Apr 97
" , " Brain 1997;120:593-604 Jun 97
" , " Brain 1997'120:963-976 Aug 97
" , " Mov Disord 1997;12:665-676 Nov 97
" , " Mov Disord 1997;12:646-654 Nov 97
" , " Brain 1997;120:2093-2111 Dec 97
" , diagnostic Arch Neur 1997;54:450-454 May 97
" , guidance Brain 1997;120:977-990 Aug 97
" , " Brain 1998;121:167-177 Mar 98
" , planning Mov Disord 1999;14:69-79 Mar 99
" rehearsal imagery Neur 2000;55:996-1002 Nov 00
MPTP Ann Neur 1994;36:765-770 Dec 94
" J Neurosci 1996;16:7776-7782 Jan 97
" Neur 1996;47:Supp 3 Feb 97
" Mov Disord 1998;13S1:35-38 Aug 98
" effect persists Ann Neur 1999;46:598-605 Nov 99
" " " Ann Neur 2000;48:127 Aug 00
" imperfect model J Neur N'surg Psych 2000;68:313-316 Apr 00
" dose-sensitive Mov Disord 2000;15:459-466 Jul 00
Multiple System AtrophyAnn Neur 1995;37:204-210 Mar 95
" J Neur N'surg Psych 1995;59:144-151 Sep 95
" Clin Neuropharm 1997;20:2399-244 Sep 97
" Arch Neur 1999;56:90-94 Mar 99
" distinct from PD JAMA 5 July 2000;44-45 Aug 00
Muscimol Lancet 31 Jan 98:341-342 Mar 98
" for ET Ann Neur 1999;46:249-252 Sep 99
Muscle, sound from Lancet 22 Feb 97;533-535 Apr 97
Myoclonus in PD Mov Disord 1998;13:540-544 Sep 98
NAC (of alpha-synucl) Ann Neur 2000;47:632-640 Jun 00
Naphtoxazine Clin Neuropharm 1998;21:108-117 Jun 98
Nerve growth factor J Neurosurg 1996;84:685-689 Apr 96
" J Neurosci 1996;16:5437-5442 Nov 96
" J Neurosci 1996;16:6433-6442 Nov 96
" J Neurosurg 1997;86:511-518 Jul 97
" and diabetes Lancet 19 Oct 96;1044-45 Nov 96
Neuroleptics (risk) J Neur N'surg Psych 1996;60:213-216 Mar 96
" malignant synd. Neur 1999;52:777-781 Apr 99
" Clin Neuropharm 1999;22:5-10 Mar 99
Neuroprotection Mov Disord 1998;13S1:46-48 Jul 98
" Cannes 97 Sym Ann Neur 1998;44 Supp 1 Oct 98
" and STN Ann Neur 1999;45:640-651 Jun 99
" "parkin" gene Ann Neur 1999;45:655-658 Jun 99
Neuroregeneration Lancet 7 Nov 98;1529 Dec 98
" BMJ 7 Nov 98;1272 Dec 98
" Nat Med 1998;4:1313-1317 Dec 98
" BMJ 22 Jan 2000:204 Mar 00
Neurosciences Inst. Science 27 Oct 1995;572: Dec 95
Neurotrophic factors Ann Neur 1996;40:346 Oct 96
" problems Nat Med 1997;3:497 Jul 97
" (BDNF) J Neurosci 1997;17:2295-2313 May 97
" (GDNF) WSJ 21 Mar 1996: Apr 96
" " Mov Disord 1998;13S1:49-54 Jul 98
" J Neurosci 1996;16:8132-8139 Jan 97
Nicotine addiction Lancet 11 Jul 1998:84-85 Aug 98
" Science News 15 Aug 1998:154 Sep 98
" worsens PD Mov Disord 1999;14:1011-13 Jan 00
NMDA antagonist J Neurosci 1996;16:4231-4239 Nov 96
" J Neurosci 1997;17:2921-2927 May 97
" Mov Disord 1998;13:414-417 Jul 98
" memantine Clin Neuropharm 1999;22:273-276 Nov 99
Nurr-1 Science 11 Apr 97;248-50 May 97
" , editorial Science 11 Apr 97:202 May 97
Nurse clinicians Neur 1997;49:1580-1587 Feb 98
Nursing home vs own J Neur N'surg Psych 1999:65:492-496 Nov 99
Nutrients and PD Neur 1996;47:644-650 Oct 96
Olanzapine Clin Neuropharm 1998;21:285-288 Nov 98
" J Neur N'surg Psych 1998;65:774-777 Dec 98
" worsens motor symp Mov Disord 1999;14:1014-16 Jan 00
" " " " Neur 2000;55:789-794 Nov 00
" " " " Neur 2000;55:795-799 Nov 00
Olfaction and PD J Neur N'surg Psych 1997;62:436-446 Jul 97
" Neur 1997;49:1262-1267 Jan 98
" Neur 1997;49:1424-1431 Jan 98
" Arch Neur 1998;55:84-90 Feb 98
" and cognition Neur 1999;53:1450-1457 Dec 99
Ondansetron (Zofran) Neur 1995;45:1305-1308 Oct 95
" Neur 1996;47:1608-1609 Feb 97
" , for tremor J Neur N'surg Psych 1997;62:282-284 Apr 97
On-off effect J Neur N'surg Psych 1995;59:555 Dec 95
" J Neur N'surg Psych 1996;61:634-637 Aug 96
Onset, early vs late Mov Disord 1997;12:277-284 Aug 97
" , " Neur 1998;50:1340-1345 Jul 98
Origin of PD, hypothes Mov Disord 2000;15:795-803 Dec 00
Orthostatic tremor J Neur N'surg Psych 1999;66:681-684 Jun 99
Osteoporosis Neur 1997;49:1272-1278 Jan 98
Oxidative stress Neur 1995;45S3:55 May 95
" J Neur N'surg Psych 1995;59:90-91 Aug 95
" Ann Neur 1996;39:378-381 Apr 96
" Mov Disord 1998;13S1:24-34 Jul 98
" BMJ 12 Dec 98:1616 Feb 99
" in ALS DNA Ann Neur 1999;46:787-790 Jan 00
" marker Ann Neur 1999;46:920-924 Jan 00
Pallidopyramidal Ann Neur 1995;38:954-956 Feb 96
PALLIDOTOMY, boom in WSJ 22 Feb 95:1 Mar 95
" for dyskinesia Neur 1995;45:753-761 Jun 96
" evaluation too low Lancet 25 May 1996:1490 Jul 96
" " difficult Ann Neur 1996;39:826 Jul 96
" cautious endorsem'tJ Neur N'surg Psych 1997;62:125-132 Apr 97
" benefits last 4 yr Neur 1997;48:1273-1277 Jun 97
" mental effects Ann Neur 1997;41:834 Jul 97
" non-PD success Arch Neur 1997;54:1026-1029 Oct 97
" lasting benefits J Neurosurg 1997;87:358-367 Oct 97
" " " J Neur N'surg Psych 1999;65:511-517 Nov 99
" benefits all ages Neur 1997;49:1072-1077 Nov 97
" safe, effective Neur 1998;50:266-270 Feb 98
" " , " J Neurosurg 2000;92:375-383 May 00
" no cognitive loss Arch Neur 1998;55:1201-1208 Oct 98
" widens Ldopa windowMov Disord 1998;13:775-781 Nov 98
" lasting benefits Neur 1998;51:1755-1757 Jan 99
" helps off, not on J Neurosurg 1999;90:197-202 Mar 99
" movement study Brain 1999;122:315-327 Mar 99
" off help transient Brain 1999;122:381-382 Apr 99
" lesion site effect Brain 1999;122:405-416 Apr 99
" " " " Brain 2000;123:746-758 Jum 00
" some ben don't lastBrain 1999;122:417-425 Apr 99
" Ldopa req unchangedMov Disord 1999;14:256-261 May 99
" help bradykinesia? Brain 1999;122:895-906 Jul 99
" no cognitive loss Arch Neur 1997;54:947-950 Sep 97
" some mental change Neur 1998;51:207-215 Aug 98
" cognition debated Arch Neur 1998;55:881-883 Aug 98
" " " J Neur N'surg Psych 1998;65:148 Sep 98
" no cognitive loss J Neur N'surg Psych 1998;65:150-154 Sep 98
" " " " J Neurosurg 1999;90:1005-10 Jul 99
" " " " Neur 2000;54:1058-1064 Apr 00
" bilateral is risky J Neurosurg 1999;91:313-321 Sep 99
" effect like DBS Nat Med 1997;3:671-674 Jul 97
" " " " Nat Med 1997;3:602-603 Jul 97
" " not " " Neur 1997;49:1078-1083 Nov 97
" for bradykinesia Mov Disord 1999;14:57-62 Mar 99
" for dystonia Mov Disord 1997;12:865-870 Jan 98
" " " Mov Disord 1998;13:693-698 Sep 98
" " " J Neurosurg 1999;90:974-976 Jun 99
" for pain in PD J Neurosurg 1999;91:198-201 Sep 99
" research during J Neur N'surg Psych 1997;63:150-162 Oct 97
" alters muscle func Neur 1997;49:1278-1283 Jan 98
" complications Brain 1998;121:50-75 Mar 98
" adverse effects Neur 1998;50:434-438 Mar 98
" Ldopa symmetrical Clin Neuropharm 1998;21:135-138 Jun 98
" verbal fluency lossBrain 1998;121:659-675 Jun 98
" off gains fade Mov Disord 1998;13S1:73-82 Jul 98
" movement study J Neur N'surg Psych 1998;65:479-487 Nov 98
" gamma knife failureAnn Neur 1996;39:535-538 Jun 96
" " " defendedJ Neurosurg 1998;89:183-193 Sep 98
" history review Ann Neur 1996;40:341-343 Oct 96
" " " BMJ 25 Apr 98:1259-60 Jun 98
" " " Mov Disord 1998;13:582-588 Jul 98
" " " Brain 1999;122:2209-20 Feb 00
" , low-cost Brain 1997;120:729-737 Jul 97
" , PET scan after Ann Neur 1995;37:776-783 Jul 95
" , " " " Ann Neur 1996;39:450-459 Jun 96
" , " " " Brain 1997;120:1301-13 Oct 97
" , " " " Brain 1997;120:1315-24 Oct 97
" as last resort Lancet 4 Apr 98:998-999 May 98
" highly effective Ann Neur 1996;40:355-366 Oct 96
" PET, MRI after Neur 1997;1083-1090 Nov 97
" , staged bilateralMov Disord 1997;12:752-755 Nov 97
" , good results J Neurosurg 1998;89:194-199 Sep 98
" , delayed stroke J Neurosurg 1997;97:955-960 Jan 98
" , microguidance J Neurosurg 1996;84:194-202 Jul 96
" , microrecording J Neurosurg 1996;85:1005-1012 Jan 97
" , " vs MRI J Neur N'surg Psych 2000;69:787-791 Dec 00
" , microguidance J Neurosurg 1997:87:52-59 Aug 97
" and optic tract Neur 1998;50:258-265 Feb 98
" precision needed J Neurosurg 1998;89:630-634 Oct 98
" MRI-guided claims J Neurosurg 1999;90:95-100 Feb 99
" , MRI study after J Neurosurg 1999;90:468-477 Apr 99
" workshop recommend Arch Neur 1999;56:1064-1069 Oct 99
" cog loss transient Mov Disord 1999;14:780-789 Oct 99
" good results Lancet 13 Nov 99;1665-9 Jan 00
" " " Mov Disord 1999;14:951-957 Jan 00
" , quality of life Mov Disord 2000;15:65-70 Feb 00
" bilateral and gait Arch Neur 2000;57:198-204 Mar 00
" " " " Arch Neur 2000;57:1231-32 Sep 00
" minimal cog. loss J Neur N'surg Psych 2000;69:326-336 Oct 00
" benefits transient J Neur N'surg Psych 2000;69:337-344 Oct 00
" and postural stab. Brain 2000;123:2141-49 Nov 00
" lasting improvem't Neur 2000;55:1218-1222 Dec 00
" lesion volume Brain 2000;123:2491-500 Jan 01
Paroxetine (Paxil) Neur 1994;44:2406 Jan 95
" Neur 2000;55:1216-1218 Dec 00
" Mov Disord 2000;15:986-989 Dec 00
Pathways, neural Neur 1995;45S3:S28-S34 May 95
" Neur 1996;1032-1036 Nov 96
Patient Diaries Mov Disord 1997;12:1039-1041 Jan 98
" " Clin Neuropharm 2000;23:75-81 Jun 00
PD subtype classes Mov Disord 1999;14:10-20 Mar 99
Pedunculopontine loss Brain 2000;123:1767-83 Oct 00
Perception, auditory Mov Disord 1997;12:655-664 Nov 97
" , visual Brain 1996;119:79-87 May 96
Pergolide (Permax) Neur 1995;45S3:S5 May 95
" Neur 1995;45S3:S13-S21 May 95
" Neur 1995;45S3:S22-S27 May 95
" Mov Disord 1997;12:402-407 Aug 97
" monotherapy Neur 1999;53:573-579 Sep 99
" , risks J Neur N'aurg Psych 1999;66:79-81 Feb 99
" " Clin Neuropharm 1999;22:277-280 Nov 99
" vs. levodopa Clin Neuropharm 1998;21:358-362 Jan 99
" no imaging effect Mov Disord 1999;14:940-946 Jan 00
Personality and PD Lancet 15 Feb 97:478 Mar 97
" J Neur N'surg Psych 1998;64:262-266 Apr 98
PET diagnosis Ann Neur 1994;36:759-764 Dec 94
" Ann Neur 1994;2:176-182 Dec 94
" J Neur N'surg Psych 1995;59:597-600 Jan 96
" Neur 1995;45:1995-2004 Feb 96
" Ann Neur 1996;39:450-459 Jun 96
" Neur 1996;46:1430-1436 Jun 96
" Neur 1996;46:1200-1205 Jun 96
" Ann Neur 1996;39:650-658 Jun 96
" Brain 1996;119:585-591 Jul 96
" Neur 1996;47:462-466 Sep 96
" Ann Neur 1996;40:873-884 Mar 97
" Ann Neur 1997;41:58-64 Mar 97
" Brain 1997;120:2187-95 Feb 98
" J Neur N'surg Psych 1998;64:314-319 May 98
" Mov Disord 1998;13:268-274 May 98
" Mov Disord 1998;13;275-280 May 98
" , PD vs PSP Neur 1999;52:1221-1226 Jun 99
" , " Ann Neur 1999;46:62-69 Aug 99
" research Brain 1998;121:949-965 Jun 98
" " Nat Med 1998;4:1308-1312 Dec 98
" " Ann Neur 1998;44:758-762 Dec 98
" " J Neur N'surg Psych 1999;66 Mar 99
" " Brain 1999;122:483-485 Apr 99
" " Ann Neur 1999;46:723-731 Jan 00
" " J Neur N'surg Psych 1999;67:737-741 Jan 00
" " Arch Neur 2000;57:1237 Sep 00
" scans, questioned Science 11 Apr 97:196-198 May 97
" study of gait Brain 1999;122:1271-82 Sep 99
Physical therapy Mov Disord 2000;15:879-883 Dec 00
Piribedil skin patch Mov Disord 1999;14:336-341 May 99
" " " Clin Neuropharm 2000;23:133-142 Aug 00
Pituitary, effects on Clin Neuropharm 1996;19(1):72-80 Dec 97
" and PD Ann Neur 1981;10:398-399 Jan 98
Placebo effect in PD Clin Neuropharm 1999;22:207-212 Oct 99
" " " Neur 2000;54:710-714 Apr 00
Porphyria and PD drugs J Neur N'surg Psych 1997;62:562 Jul 97
Post-encephalitis PD Ann Neur 1997;42:356-359 Oct 97
Post-stroke PD Neur 2000;54:2182-2184 Jul 00
Posture, stooped Mov Disord 1999;14:443-447 Jun 99
Posturography for diag Arch Neur 2000;57:1464-1469 Nov 00
POW camp stress Lancet 18 Dec 99;2116-18 Jan 00
" " " Lancet 4 Mar 00;843 Apr 00
Pramipexole (Mirapex) PDF Newsletter Spr 1996:1 Apr 96
" JAMA 9 Jul 87:125-130 Aug 97
" Neur 1997;49:162-168 Aug 97
" Neur 1997;49:724-728 Oct 97
" Neur 1997;49:1060-1065 Nov 97
" Clin Neuropharm 1998;21:141-151 Jul 98
" and PSP Neur 1999;52:873-874 Apr 99
" and driving Lancet 12 Jun 99:2043 Jul 99
" " " Neur 1999;52:1908-1910 Jul 99
" for tremor Clin Neuropharm 1999;22:301-305 Nov 99
Preclinical period J Neur N'surg Psych 1998;64:314-319 May 98
Pregnancy and PD Mov Disord 1998;13:34-38 Mar 98
" Mov Disord 2000;15:132-135 Feb 00
Prevalence J Neur N'surg Psych 1997;62:10-15 Mar 97
" Mov Disord 1998;13:626-632 Sep 98
" , Afro-Carib Mov Disord 2000;15:18-23 Feb 00
" , London area BMJ 1 Jul 00;21-22 Aug 00
" Lower Aragon, SpainMov Disord 1999;14:506-604 Sep 99
" questionnaire J Neur N'surg Psych 2000;69:117-120 Aug 00
Prions Science News 13 Apr 1996;228 May 96
Prodromal phase Mov Disord 1997;12:871-876 Jan 98
Progenitor cells Eng. & Sci (CIT) Sept 95:26 Nov 95
" neurons Arch Neur 1999;56:780-784 Aug 99
Progression (case hist)NEJM 1996;334:116-118 Feb 96
" JAMA 6 Mar 1996:716 Apr 96
" JAMA 9 Oct 1196;1171 Nov 96
" , in putamen Brain 1996;119:2097-103 Mar 97
" , rate Arch Neur 1999;56:334-337 May 99
" , " Mov Disord 2000;15:479-484 Jul 00
" , " Mov Disord 2000;15:485-489 Jul 00
" , " J Neur N'surg Psych 2000;69:313-318 Oct 00
" , " vs MSA, etc Neur 2000;55:888-891 Nov 00
" indicated by PET Ann Neur 2000;47:804-808 Jul 00
Progressive Supranuc- J Neur N'surg Psych 1996;60:589 Jun 96
" lear Palsy J Neur N'surg Psych 1996;61:615-620 Aug 96
" Neur 1996;47:1-9 Sep 96
" Neur 1996;47:148-154 Sep 96
" Brain 1997;120:65-74 Apr 97
" Arch Neur 1997;54:1104-1108 Oct 97
" difference from PD Brain 2000;123:1410-21 Aug 00
PSP, MSA mistaken Lancet 20 Nov 99;1771-5 Jan 00
" " " Lancet 3 Feb 2000;495-6 Mar 00
" " " Lancet 26 Feb 00;754-5 Apr 00
" " related Ann Neur 2000;47:374-377 Apr 00
Propath program Arch Neur 1996;53:881-884 Oct 96
Propranolol (Inderal) Neur 1996;46:1548-1551 Jul 96
" with gabapentin Arch Neur 2000;57:570-571 Jun 00
Proprioception deficit J Neur N'surg Psych 1999;65:504-510 Nov 99
" " Ann Neur 2000;47:218-228 May 00
Proton Magnetic Res. J Neur N'surg Psych 1997;62:239-242 Apr 97
" " " Mov Disord 1997;12:903-909 Jan 98
Prozac (fluoxetine) Neur 1995;45:1855-1858 Nov 95
Pseudo-fatigue Ann Neur 1998;44S1:189-196 Oct 98
Psychogenic PD Arch Neur 1995;52:802-810 Sep 95
Psychosis Rating Scale Clin Neuropharm 1998;21:280-284 Nov 98
" treatment Clin Neuropharm 1998;21:285-288 Nov 98
" , drug-induced Mov Disord 2000;15:201-211 May 00
Psyllium Mov Disord 1997;12:946-951 Jan 98
Punding, drug-related Mov Disord 1999;14:836-838 Oct 99
Quality of life J Neur N'surg Psych 1996;61:71-74 Aug 96
" Mov Disord 1997;12:916-922 Jan 98
" Mov Disord 2000;15:216-223 May 00
" J Neur N'surg Psych 2000;69:308-312 Oct 00
" and fetal transpl Mov Disord 2000;15:224-229 May 00
" " pallidotomy Mov Disord 2000;15:230-237 May 00
" evaluation J Neur N'surg Psych 2000;69:67-73 Aug 00
" PD impact survey J Neur N'surg Psych 2000;69:584-589 Dec 00
Quetiapine (Seroquel) Mov Disord 1999;14:484-487 Jun 99
" " Ann Clin Psych 1999;11:141-144 Oct 99
" vs clozapine Neur 2000;55:899 Nov 00
Raclopride, in PET Mov Disord 1997;12:33-38 Feb 97
Rapid-onset Neur 1997;49:1066-1069 May 97
" " new kindred Neur 2000;55:991-995 Nov 00
Rating scale, clinical Clin Neuropharm 1997;20:183-184 Sep 97
" " Clin Neuropharm 1997;20:322-327 Sep 97
Reaction time J Neur N'surg Psych 1995;59:499-506 Dec 95
" Brain 1996;119:1689-1704Jan 97
Recent advances JAMA 27 Jan 99:376-378 Feb 99
Receptors, distribut Brain 1999;122:1449-68 Sep 99
Redundant pathways J Neur N'surg Psych 1998;64:164-171 Apr 98
Reflex blink, and PD J Neurosci 1996;16:7308-7330 Dec 96
Regeneration, brain Lancet 16 Mar 1996:751 Apr 96
" Science News 21 Sep 1996:180 Oct 96
" Science 28 Feb 97;1318-19 Apr 97
" Nat Med 1998;4:555-557 Jun 98
" , natural Science News 18 Mar 2000:180 Apr 00
" , neural Nat Med 1997;3:1329-1235 Jan 98
" , spinal cord Lancet 21 Sep 1996:814 Oct 96
Registry (surveys) Neur 1995;45:1991-1995 Feb 96
" NEJM 1996;334:71-76 Feb 96
" Neur 1995;45:2143-2146 Feb 96
" Arch Neur 1996;53:66-71 Feb 96
Remacemide, NMDA antag Clin Neuropharm 1999;22:220-225 Sep 99
" safety trial Neur 2000;54:1583-1588 May 00
Research priorities JAMA 25 Oct 95:1257-8 Nov 95
" prospects Lancet 13 Feb 99:466 Mar 99
" " BMJ 1999;318:311-314 Mar 99
Response time, levodopaNeur 1996;46:1055-1058 Jun 96
" Neur 1996;46:1059-1062 Jun 96
Restless legs syndrome JAMA 17 Jan 1996: Feb 96
" Neur 1996;47:1435-1441 Feb 97
" Clin Neuropharm 1997;20:148-151 May 97
" Mov Disord 1997;12:402-407 Aug 97
" Neur 1999;52:932-937 Apr 99
" and C-M-T Neur 1999;52:1064-1066 Apr 99
" needs study Neur 1999;52:907-910 Apr 99
" pergolide for Neur 1999;52:944-950 Apr 99
" pramipexole forNeur 1999;52:938-943 Apr 99
Retina, dopamine cells Neur 1999;52:541-546 Mar 99
Rigidity Mov Disord 1997;12:24-32 Feb 97
" rating scales Mov Disord 2000;15:48-55 Feb 00
Riluzole (Rilutek) Lancet 22 May 99:1764-5 Jul 99
" for LID Lancet 7 Aug 99:511 Sep 99
Rimantadine Clin Neuropharm 1999;22:30-32 Mar 99
Risperidone Mov Disord 1997;12:119-121 Feb 97
" Mov Disord 1997;12:610-612 Sep 97
" J Neur N'surg Psych 1998;64;135 Feb 98
" Clin Neuropharm 1998;21:285-288 Nov 98
" Mov Disord 2000;15:301-304 May 00
Ropinirole (Requip) Neur 1997;49:393-399 Oct 97
" Mov Disord 1998;13:39-45 Mar 98
" Mov Disord 1998;13:46-51 Mar 98
" Clin Neuropharm 1998;21:101-107 Jun 98
" Arch Neur 1998;55:1211-1216 Oct 98
" Neur 1998;51:1057-1062 Nov 98
" efficacy BMJ 1 Jul 00:1-2(ed) Aug 00
" and driving Lancet 12 Jun 99:2043 Jul 99
" " " Neur 1999;52:1908-1910 Jul 99
" and dyskinesia Mov Disord 1998;13:234-241 May 98
" safety trial Clin Neuropharm 1998;21:164-175 Jul 98
" vs bromocriptine Neur 1999;53:364-370 Sep 99
Rotenone PD risk Lancet 11 Nov 00:1659 Dec 00
" BMJ 11 Nov 00:1175 Dec 00
Salivation less in PD Clin Neuropharm 1999;22:213-215 Sep 99
Salsolinol Ann Neur 1996;40:119-122 Aug 96
" Ann Neur 1998;43:212-216 Mar 98
" Lancet 21 Mar 98:850-851 Apr 98
Schizophrenia, dop and Lancet 16 Sep 00:958-959 Nov 00
Scintigraphy of heart Neur 1999;53:1020-25 Nov 99
Scopolamine, psychosis Neur 1999;53:453-454 Sep 99
Selegiline, amphetamineLancet 1995;346:64 Oct 95
" slows AD progress NEJM 14 Apr 97:1216-22 May 97
" protection debated Ann Neur 1995;37:95-98 Feb 95
" reduces Ldopa req Mov Disord 1997;12:175-182 May 97
" protection debated Ann Neur 1997;41:833-834 Jul 97
" reduces Ldopa req Ann Neur 1998;43:613-617 Jun 98
" aids motor control Clin Neuropharm 1999;22:54-59 Mar 99
" , DATATOP, dubious Arch Neur 1995;52:237-245 Apr 95
" , " endpoint Arch Neur 1995;52:564-570 Nov 95
" , " , no LID help Ann Neur 1996;39:37-45 Mar 96
" , " , help brief Ann Neur 1996;39:29-36 Mar 96
" , " , mortality Ann Neur 1998;43:318-325 Apr 98
" min dosage needed Mov Disord 1997;12:293-296 Aug 97
" , in favor of PDF Newsletter Spr 1996:2 Apr 96
" causes hypotension Mov Disord 1999;14:246-251 May 99
" , PET study Ann Neur 1994;36:759-764 Dec 94
" , pro and con BMJ 16 Mar 96:702-705 Apr 96
" protection debated Ann Neur 1996;40:266-269 Sep 96
" , Brits reply Ann Neur 1997;41:282-283 Mar 97
" is protective Ann Neur 1995;38:771-777 Jan 96
" " " J Neurochem 1997;68:33-39 Aug 97
" " " J Neurochem 1997;68:434-436 Aug 97
" " " Neur 1998;51:520-525 Sep 98
" reduces stroke damaPharmacol Toxicol 1998;83:194-199 Feb 99
" risk debate goes onBMJ 16 Dec 95:1602-7 Jan 96
" , reply to Brits Ann Neur 1996;40:841-845 Mar 97
" risks hypotension Neur 1997;48:662-667 Apr 97
" mortality normal Clin Neuropharm 1997;20:276-278 Sep 97
" risks hypotension J Neur N'surg Psych 1997;63:228-234 Oct 97
" mortality debated Clin Neuropharm 1997;20:542 Feb 98
" debate goes on BMJ 18 Apr 98;1191-96 May 98
" mortality normal BMJ 25 Jul 98:252-255 Sep 98
" hypotension rebutt J Neur N'surg Psych 1998;65:280-282 Sep 98
" mortality normal Neur 1998;51:825-830 Oct 98
" mortality normal BMJ 5 Dec 98:1586-87 Jan 99
" , special review Neur 1996;47:Supp 3 Feb 97
" non-stim=Zelapar J Neur N'surg Psych 1999;66:2nd cover May 99
" accumulates Clin Neuropharm 2000;23:22-27 Mar 00
Semantic impairment Arch Neur 2000;57:1338-1343 Nov 00
Sensory processing Brain 1999;122:1651-65 Oct 99
Serotonin agonist Neur 1997;49:1168-1170 Nov 97
" " Mov Disord 1997;12:756-759 Nov 97
" antagonist Clin Neuropharm 1997;20:300-310 Sep 97
" syndrome Neur 1997;48:1070-1077 Mar 97
Sertoli cells Nat Med 1997;3:1129-1132 Nov 97
Sexuality and PD Mov Disord 1997;12:923-927 Jan 98
Sex life affected J Neur N'surg Psych 2000;69:550-552 Nov 00
Shy-Drager Ann Neur 1995;37:204-210 Mar 95
SIB-1508Y Ann Neur 1998;43:311-317 Apr 98
" Mov Disord 1998;13:637-642 Sep 98
Sildenafil (Viagra) Mov DIsord 2000;15:305-308 May 00
Sinemet, dissolved Mov Disord 1997;12:608-610 Sep 97
Sinemet CR J Neur N'surg Psych 1995;58:ad Jul 95
" Lancet 11 Nov 95:1290 Dec 05
" Mov Disord 1997;12:677-681 Nov 97
" Clin Neuropharm 1994;17S2:1-6 May 98
" Clin Neuropharm 1999;22:33-39 Mar 99
" Clin Neuropharm 1999;22:74-79 May 99
" vs regular Neur 1999;53:1012-19 Nov 99
" " " Neur 2000;55:156-157 Aug 00
Sjogren's syndrome Mov Disord 1997;12:121-123 Feb 97
Skull fracture and PD J Jeur N'surg Psych 1999;66:380-385 Apr 99
Sleep attacks Lancet 12 Jun 99:2043 Jul 99
" " Neur 1999;52:1908-10 Jul 99
" " Neur 2000;54:274-277 Feb 00
" ", pramipexole Mov Disord 2000;15:658-653 Oct 00
" benefit Mov Disord 1997;12:506-508 Sep 97
" " Neur 1998;50:1332-1339 Jul 98
" " J Neur N'surg Psych 1999;67:384-385 Oct 99
" disorder Mov Disord 1998;13:895-899 Dec 98
" " Mov Disord 1999;14:117-121 Mar 99
" RBD/REM in PD Brain 2000;123:1155-60 Jul 00
" " , hallucinatons Neur 2000;55:281-288 Sep 00
" , violence in Lancet 19 Apr 97:1150 Jun 97
" , " Neur 1998;51:526-529 Sep 98
Sleepiness, excessive Mov Disord 1999;14:922-927 Jan 00
Smell, loss of J Neur N'surg Psych 1997;62:436-446 Jul 97
" , " Neur 1997;49:1262-1267 Jan 98
" , " Arch Neur 1998;55:84-90 Feb 98
" , " Mov Disord 1998;13:394-399 Jul 98
Smoking and PD Neur 1995;45:1041 Sep 95
" Neur 1995;58:294-298 Oct 95
" Time 11 Mar 96:60 Apr 96
" Lancet 24 Feb 96:527 Apr 96
" Ann Neur 1996;39:378-381 Apr 96
" Neur 1996;46:1275-1284 Jun 96
" Neur 1997;49:1267-1272 Jan 98
" Neur 1999;52:115-119 Feb 99
" Neur 1999;53:1158 Nov 99
" " " and MAO-B Neur 1998;50:1458-1461 Jul 98
" " " and heredity J Neur N'surg Psych 2000;69:535-537 Nov 00
SPECT, diagnosis by Neur 1996;46:278-285 Apr 96
" , " Neur 1996;46:231-237 Apr 96
" , " Brain 1997;120:103-110 Apr 97
" , " J Neur N'surg Psych 1997;62:133-140 Apr 97
" , " Mov Disord 1997;12:898-902 Jan 98
" , " Mov Disord 1998;13:16-19 Mar 98
" , " Mov Disord 1998;13:438-445 Sep 98
" , " Neur 1999;52:1206-1214 Jun 99
" , " Mov Disord 1999;14:430-435 Jun 99
" , " Lancet 21 Aug 99:646-647 Oct 99
" , " J Neur N'surg Psych 2000;68:263 Mar 00
" , " Mov Disord 2000;15:503-510 Jul 00
" , research using Mov Disord 2000;15:692-698 Oct 00
Speech impairment Neur 2000;54:458-462 Mar 00
" " J Neur N'surg Psych 2000;69:319-325 Oct 00
Speech therapy Neur 1996;47:1496-1504 Feb 97
Square wave jerks Neur 1999;52:185-188 Feb 99
Startle reflex Neur 1998;51:1315-1320 Dec 98
" Neur 1998;51:1315-1320 Jan 99
Stem cells, cultured Science News 19 Jul 97:36 Aug 97
" , review of Science 4 Apr 97:66-71 May 97
" , " Lancet 17 Jun 00:2142 Jul 00
" , transplant BMJ 12 Jun 99:1575: Jul 99
" , " Proc Nat Acad Sci 1999;96:7029-34 Jul 99
" , opposition to Lancet 26 Aug 00:693 Oct 00
" , ethical issues JAMA 27 Dec 00:3175,80 Jan 01
" , regulation BMJ 9 Dec 00:1427 Jan 01
Stem cells, scaffold Lancet 28 Oct 00:1500 Dec 00
Stereotactic J Neurosurg 1995;83:197-205 Aug 95
" Science News 30 Mar 96:204 Apr 96
" J Neurosurg 1998;88:777-781 Jun 98
Stimulation, chronic Neur 1996;46:1150-1153 Jun 96
" Arch Neur 1996;53:898-903 Oct 96
" Neur 1997;49:1078-1083 Nov 97
STNucleotomy, cognitiv J Neur N'surg Psych 2000;69:60-66 Aug 00
Strategy, summary Clin Neuropharm 1997;20:95-115 May 97
Strength, arm Ann Neur 1996;39:79-88 Mar 96
" Brain 1997;120:401-408 Jun 97
Striatonigral degener- Neur 1996;47:1032-1036 Nov 96
Striatal cell types Neur 2000;55:1249-1255 Dec 00
Stroke, help from Mov Disord 1997;12:124-126 Feb 97
" , adverse effect J Neur N'surg Psych 1997;62:288-289 Apr 97
" , " Neur 1997;49:707-710 Oct 97
" , " Nat Med 1997;3:1129-1132 Nov 97
" , " Mov Disord 1997;12:1035-1038 Jan 98
Stuttering and L-dopa J Neur N'surg Psych 1999;66:776-778 Jul 99
Substantia nigra DBS Science News 28 Nov 98:344 Dec 98
" detailed anatomy Brain 1999;122:1401-02 Sep 99
" " " Brain 1999;122:1421-36 Sep 99
" , PD progress in Brain 1999;122:1437-48 Sep 99
Surgery, holographic J Neurosurg 1998;88:777-781 Jun 98
" , summary J Neur N'surg Psych 1997;62:2-8 Mar 97
" , " BMJ 25 Apr 98:1259-60 Jun 98
" , review Science News 27 Nov 99;342 Jan 00
" , " Neur 1999;53:1910-21 Feb 00
" , " Arch Neur 2000;57:1118-25 Sep 00
" , " (book) Ann Neur 1998;44:843-844 Dec 98
Swallowing Neur 1997;48:373-375 Mar 97
" Mov Disord 1997;12:322-327 Aug 97
" J Neur N'surg Psych 1997;63:579-583 Jan 98
" Brain 2000;123:1863-73 Oct 00
Sweats, control of Ann Neur 1995;37:120-122 Mar 95
Symmetrel (Amantadine) Neur 1996;46:1551-1556 Jul 96
Synphilin-1 Ann Neur 2000;47:521-523 May 00
Tachyphemia Mov Disord 1997;12:302-305 Aug 97
Tacrine, PD symptoms J Neur N'surg Psych 1996;61:324-325 Oct 96
Tactile acuity Neur 1997;49:168-177 Aug 97
Tardive dyskinesia Mov Disord 1997;12:119-121 Feb 97
" " , and PVP Lancet 15 Mar 97:777 Apr 97
Technology review BMJ 13 Nov 1999 all Jan 00
Terguride Clin Neuropharm 1996;19(1):72-80 Dec 97
Tetanus shot caused J Neur N'surg Psych 1997;63:258 Oct 97
Thalamotomy J Neur N'surg Psych 1996;60:564-571 Jun 96
" Brain 1996;119:1717-27 Jan 97
" Ann Neur 1997;41:108-111 Mar 97
" J Neurosurg 1998;89:314-316 Sep 98
" for ET J Neur N'surg Psych 1999;66:772-775 Jul 99
" " " Neur 2000;55:443-446 Sep 00
Thalamus, and tremor Neur 1996;46:75-79 Mar 96
" , " " J Neur N'surg Psych 1999;66:794-796 Jul 99
" Neur 1996;46:1150-1153 Jun 96
" , role in PD Mov Disord 1999;14:481-483 Jun 99
Theophylline helps PD Neur 1999;52:1916 Aug 99
Therapy, tutorial Western J Med 1994;161:303-308 Jul 96
" " Postgrad Med 1996;99:52-68 Jul 96
" " Sci Amer Medicine Part 11, Chap XV Dec 97
" " Arch Neur 1999;56:785-790 Aug 99
" " BMJ 7 Aug 99:362-366 Sep 99
", Kobe 1997 Sym Neur 1998;51 Supp 2 Oct 98
Time, judgement of Science News 17 Feb 96:101 Mar 96
" Brain 1996;119:51-70 May 96
" J Neur N'surg Psych 1998;65:921-923 Jan 99
Tirilizad in transplantBrain 2000;123:1380-90 Aug 00
Tocopherol Neur 1998;50:1900-1902 Aug 98
Tolcapone (Tasmar) Neur 1997;48:81-87 Feb 97
" Lancet 6 Sep 97:712 Oct 97
" J Neur N'surg Psych 1997;63:421-428 Nov 97
" Neur 1997;1066-1071 Nov 97
" Mov Disord 1997;12:928-934 Jan 98
" Clin Neuropharm 1997;20:531-541 Feb 98
" Lancet 25 Apr 98:1221-22 Jun 98
" and confusion Lancet 27 Jun 98:1995-96 Nov 98
" , liver failure Lancet 19 Sep 98:958 Oct 98
" " " Lancet 19 Sep 98:958 Jan 99
" " " Roche Labs leaflet 1998 (1st version)Jan 99
" , protective Pharmacol Toxicol 1998;83:194-199 Feb 99
" toxicity Lancet 17 Oct 98:1313-14 Nov 98
" trial Neur 1998;50S5:S15-S16 Aug 98
" " Neur 1998;50S5:S31-S38 Aug 98
" " Neur 1997;49:665-671 Aug 98
" " J Neur N'surg Psych 1997;63:421-428 Aug 98
" " Neur 1997;49:1066-1071 Aug 98
" " Mov Disord 1998;13:643-647 Sep 98
" " Arch Neur 1998;55:1089-1095 Oct 98
" " Clin Neuropharm 1999;22:24-29 Mar 99
" v bromocriptine Mov Disord 1999;14:38-44 Mar 99
" safety declared Arch Neur 2000;57:205-208 Mar 00
" withdrawal test Clin Neuropharm 2000;23:98-105 Jun 00
" diarrhea, gene? Clin Neuropharm 2000;23:143-148 Aug 00
Toluene (glue sniffing)J Neur N'surg Psych 1999;66:794-796 Jul 99
Topiramate Lancet 3 Oct 98:1119 Jan 99
Tourette Syndrome Mov Disord 1997:12:402-407 Aug 97
Toxins, environmental Ann Neur 1994;36:765-770 Dec 94
" Neur 1995;45:435-439 Apr 95
" Neur 1995;45:2112 Feb 96
" Neur 1997;48:1583-1588 Jul 97
Tracking, visual Brain 1995;118:485-493 Jul 95
Transcranial mag. stim J Neurosci 1997;17:3178-3184 May 97
" Mov Disord 1997;12:315-321 Aug 97
" Neur 1999;52:768-770 Apr 99
" and RLS Neur 1999;52:1060-1063 Apr 99
Tremor, action Mov Disord 1998;13:56-60 Mar 98
", " Mov Disord 2000;15:244-254 May 00
", budipine for Clin Neuropharm 1999;22:115-119 May 99
", cerebellar J Neur N'surg Psych 1997;62:282-284 Apr 97
", classses of J Neur N'surg Psych 1999;67:646-650 Dec 99
", diagnosis by Ann Neur 1999;46:126-128 Aug 99
", DBS (STN) for Mov Disord 1998;13:907-914 Dec 98
", oscillators Mov Disord 2000;15:84-94 Feb 00
", resting PD Neur 1996;46:1359-1370 Jun 96
", " Neur 1998;51:803-810 Oct 98
", surgery for J Neurosurg 1997;86:642-647 May 97
", workshop Mov Disord 1998;13:Supp 3 Dec 98
", analysis of Mov Disord 2000;15:683-691 Oct 00
Trihexyphenidyl(Artane)Ann Neur 1997;41:133 Mar 97
Tropical fruit, herbal Lancet 24 Jul 99:281-86: Sep 99
Ubiquitin Brain 1995;118:1447-49 Feb 96
Ultrasound of s. nigra Neur 1995;45:182-184: Nov 99
" early warning of PDNeur 1999;53:1026-31: Nov 99
UPDRS Mov Disord 1998;13:533-636 Sep 98
" validated Mov Disord 1999;14:585-589 Sep 99
Urinary dysfunction J Neur N'surg Psych 1997;62:507-511 Jul 97
" " Mov Disord 1997;12:509-513 Sep 97
Valproate Neur 1996;47:626-635 Oct 96
Vascular parkinsonism Arch Neur 1999;56:98-102 Mar 99
Virus, parkinsonism Neur 1999;53:1781-86 Jan 00
Vision abnormality Neur 1995;45:1144-1148 Oct 95
" " Mov Disord 1998;13:446-452 Sep 98
" " Clin Neuropharm 1998;21:289-295 Nov 98
Visual cues and gait Brain 1999;122:111-120 Aug 99
" " " " Brain 2000;123:2077-90 Nov 00
" perception Brain 1996;119:79-87 May 96
" " Brain 1997;120:2219-28 Feb 98
Visuomotor control Neur 1998;50:1648-1654 Aug 98
" " Brain 1999;122:303-313 Mar 99
Visuospatial attention Brain 1995;118:153-166 Jun 95
" memory Mov Disord 1999;14:80-86 Mar 99
Vitamin D Neur 1997;49:1273-1278 Jan 98
" E Neur 1998;50:1900-1902 Aug 98
Voice loudness J Neur N'surg Psych 1999;67:199-202 Sep 99
Voice tremor and DBS Neur 1998;50:796-798 Apr 98
Voiding dysfunction J Neur N'surg Psych 2000;68:429-433 May 00
Vulnerability, neuron Mov Disord 1999;14:206-218 May 99
Walking stride length Mov Disord 1998;13:61-69 Mar 98
" " timing Mov Disord 1998;13:428-437 Sep 98
" , brain activity Brain 1999;122:1349-55 Sep 99
Wasp sting Mov Disord 1999;14:122-127 Mar 99
Weight loss Neur 1997;48:88-91 Feb 97
Wine and dementia BMJ 5 Apr 97:997 May 97
" " longevity BMJ 28 Feb 98:648 Apr 98
Xenotransplant risk Lancet 6 Feb 99:476 Mar 99
" " Lancet 23 Sep 00:717-718 Nov 00
" " Lancet 23 Sep 00:1049-50 Nov 00
" ready for approv. Lancet 13 Nov 99;1658 Jan 00
" objections Lancet 29 Jan 2000:497-8 Mar 00
Yawn when turning on Neur 1998;50:823 Apr 98
Yohimbine (Yocon) Clin Neuropharm 1999;22:172-175 Aug 99
Young onset Neur 1996;47:225-230 Sep 96
" " Mov Disord 1997;12:277-284 Aug 97
" " Mov Disord 1998;13:885-894 Dec 98
Zelapar J Neur N'surg Psych 1999;66:2nd cover May 99
Zolpidem (Ambien) Lancet 26 Apr 97:1222-23 Jun 97
" Lancet 5 Jul 97:74 Aug 97
" injures liver BMJ 1 May 99:1179 Jun 99
" mental effects Clin Neuropharm 2000;23:54-58 Mar 00
| Index |
updated 2001/01/11